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ABSTRACT
Candida albicans is a major fungal pathogen of humans. It exists as a commensal in the oral cavity, gut or genital tract of
most individuals, constrained by the local microbiota, epithelial barriers and immune defences. Their perturbation can lead
to fungal outgrowth and the development of mucosal infections such as oropharyngeal or vulvovaginal candidiasis, and
patients with compromised immunity are susceptible to life-threatening systemic infections. The importance of the
interplay between fungus, host and microbiota in driving the transition from C. albicans commensalism to pathogenicity is
widely appreciated. However, the complexity of these interactions, and the significant impact of fungal, host and
microbiota variability upon disease severity and outcome, are less well understood. Therefore, we summarise the features
of the fungus that promote infection, and how genetic variation between clinical isolates influences pathogenicity. We
discuss antifungal immunity, how this differs between mucosae, and how individual variation influences a person’s
susceptibility to infection. Also, we describe factors that influence the composition of gut, oral and vaginal microbiotas, and
how these affect fungal colonisation and antifungal immunity. We argue that a detailed understanding of these variables,
which underlie fungal-host-microbiota interactions, will present opportunities for directed antifungal therapies that benefit
vulnerable patients.
Keywords: Candida; Candida infections; antifungal immunity; microbiota; mycobiota; fungus-host-microbiota interactions;
patient variability; fungal variability; microbiota variability
INTRODUCTION
Fungal pathogens have a major global impact upon human
health. Estimates suggest that, at any given time, over a quar-
ter of the world’s population have a fungal infection of the skin,
that 75% of women suffer at least one episode of vulvovagi-
nal candidiasis during their lifetime, and that over a million
people die each year from an invasive fungal infection (Brown
et al. 2012). Mortality rates for those suffering systemic fungal
infections are unacceptably high, reaching 50% in many cases.
This is because fungal infections are often difficult to diag-
nose, and are particularly challenging to treat (Perlroth, Choi
and Spellberg 2007; Brown et al. 2012; Köhler, Casadevall and
Perfect 2014). There is a clear and urgent medical need for
more accurate diagnostics, for safer and more effective anti-
fungal drugs, and for host-directed therapies. The search for
antifungal drug targets is somewhat constrained by the fact
that, as eukaryotes, fungi share fundamental mechanisms of
cell growth and division with humans. The search for diagnos-
tic markers that can distinguish infection from fungal com-
mensalism is especially challenging. Therefore, the develop-
ment of potent new clinical tools is dependent upon a compre-
hensive understanding of fungal pathogenicity and antifungal
immunity.
Candida species are amongst the top fungal killers (Brown
et al. 2012). Of these, Candida albicans remains the most com-
mon cause of life-threatening systemic candidiasis, although
the frequent prophylactic use of azole antifungal drugs has led
to the emergence of other Candida species with intrinsic resis-
tance to these drugs (Nguyen et al. 1996; Silva et al. 2012; Chowd-
hary, Sharma and Meis 2017). Nevertheless, in this review we
focus on C. albicans, because a combination of three main factors
arguably makes this species unique amongst fungal pathogens:
(a) its lifestyle as both a commensal and potent pathogen; (b)
the range and frequency of infections that it causes; and (c) its
pathobiology has been studied in greater depth than most other
fungal pathogens.
Candida albicans is an opportunistic pathogen that exists as
a commensal in most individuals, and is a frequent cause of
mucosal and systemic infections (See The Fungus). Unlike most
fungal pathogens, C. albicans is generally considered to be obli-
gately associated with warm-blooded animals (Odds 1988). Envi-
ronmental isolates of C. albicans continue to be reported (Bensas-
son et al. 2019; Maciel et al. 2019; Opulente et al. 2019). However,
although the existence of an environmental reservoir cannot be
excluded, it is apparently not necessary for human colonisation.
Candida albicans is transmitted vertically from mother to
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Figure 1. Three-way interactions between the fungus, the host and the local
microbiota strongly influence the likelihood and severity of C. albicans infections.
See text.
microbiota rather than other sources (d Enfert 2009; Miranda
et al. 2009; Zhai et al. 2020) (see The Microbiota). This contrasts
with other major pathogens such as Aspergillus, Cryptococcus
and Histoplasma species, which are fundamentally environmen-
tal fungi that have evolved traits that promote pathogenicity in
humans, possibly through their transient passage in niches that
have similarities with those encountered in the human host, for
example, their association with rodents or contact and evasion
of amoebic predation in the environment (Steenbergen, Shu-
man and Casadevall 2001; Malliaris, Steenbergen and Casade-
vall 2004; Van Waeyenberghe et al. 2013; Hillmann et al. 2015).
Pneumocystis jirovecii is obligately associated with humans, but
this major pathogen differs from C. albicans in that it is unable
to thrive outside its host (Liu, Fahle and Kovacs 2018). Con-
sequently, key aspects of Pneumocystis jirovecii biology remain
unexplored. The lifestyle of C. albicans even differs considerably
from its distant cousin, C. (Brunke and Hube 2013; Kasper, Sei-
der and Hube 2015). Genetic evidence suggests that, although it
is often presumed to be a human commensal such as C. albicans,
C. glabrata seems to be only secondarily associated with humans
and is likely to have environmental reservoirs (Gabaldón and
Fairhead 2019).
The biology, epidemiology, pathogenicity and immunology
of C. albicans have been studied in greater depth than for any
other fungal pathogen. This depth of knowledge provides a
strong platform for studies of the relationships between the
fungal pathogen, host immunity and local microbiota that lie
at the heart of fungal infection (Casadevall and Pirofski 1999,
2003, 2015; Jabra-Rizk et al. 2016) (Fig. 1). Other major fungal
pathogens infect humans by different routes to C. albicans,
but many principles that are emerging for C. albicans may be
applicable to these pathogens. Therefore, we present underlying
principles of C. albicans colonisation and infection, antifungal
immune defences, and the protective properties of the local
microbiota in the gastrointestinal (GI) tract, oral cavity and
vagina. We also address the variability that influences the
Fungus-Host-Microbiota interplay and how this impacts infection.
A detailed understanding of this tripartite interplay is essential
to optimise therapeutic strategies for individual patients (d
Enfert 2009; Pirofski and Casadevall 2020).
THE FUNGUS
C. albicans commensalism and pathogenicity
C. albicans frequently inhabits the oral, vaginal and GI mucosa of
healthy individuals as a harmless commensal (Ghannoum et al.
2010; Drell et al. 2013; Nash et al. 2017) (Fig. 2). Indeed, C. albicans
is present on the mucosa of most people in most human pop-
ulations (Neville, d Enfert and Bougnoux 2015; Prieto et al. 2016;
Mishra and Koh 2018). However, this fungus can cause infections
if the local microbiota becomes perturbed, normal tissue barri-
ers are weakened or immune defences become compromised.
Mucosal infections, characterised by fungal colonisation (i.e.
overgrowth) associated with an inflammatory host response, are
extremely common and can have a major impact upon the qual-
ity of life for many individuals (Fig. 2). For instance, most women
of reproductive age (75%) will experience at least one episode of
VVC (‘thrush’) in their lifetime, and up to 9% suffer from recur-
rent VVC, as defined by multiple episodes of vaginitis per annum
(Foxman et al. 2013; Yano et al. 2019; Rosati, Bruno, Jaeger, Ten
Oever et al. 2020). Risk factors for VVC include high estrogen
levels, the use of oral contraceptives and uncontrolled diabetes.
However, episodes can be idiopathic (i.e. of unknown cause) and
VVC, unlike oral candidiasis, can occur in apparently healthy
individuals (see Innate antifungal responses).
Oropharyngeal candidiasis (OPC) can broadly be classified
into three main conditions, namely acute, chronic and chronic
mucocutaneous candidiasis syndromes (Vila et al. 2020) (Fig. 2).
Predisposing factors include nutritional deficiencies, local dys-
biosis, salivary hypo-function, smoking, wearing dentures and
dysfunctional T-cell immunity due to genetic alterations or
other infections. Indeed, OPC is the most frequently diag-
nosed oral opportunistic infection in HIV-positive individuals
and many acute cases are caused by broad-spectrum antibiotic
treatments (Samaranayake 1992; Vila et al. 2020).
Life-threatening systemic C. albicans infections can arise
when the fungus enters the bloodstream (Fig. 2). Candidaemia
is the fourth most common nosocomial bloodstream infection
in North America (Pfaller and Diekema 2010), but the incidence
of invasive candidiasis in European countries is generally lower
(Meyer et al. 2013; Yapar 2014). The presence of a central venous
catheter, dialysis, antibiotic treatment, lengthy stays in inten-
sive care units (ICUs), recent major surgery, and receiving total
parenteral nutrition are among the predisposing factors for sys-
temic candidiasis (Pappas et al. 2018). Most disseminated infec-
tions arise from Candida escaping the patient’s own GI tract
(Miranda et al. 2009; Gouba and Drancourt 2015; Zhai et al. 2020).
Systemic infections arise when host defences are compromised
by, for example, damage to the intestinal barrier (e.g. surgery
or trauma), medically induced immunosuppression (corticos-
teroids or chemotherapy-induced neutropenia), or the use of
broad-spectrum antibiotics (Pappas et al. 2018). A combination
of these factors is typically needed to allow C. albicans to translo-
cate from the gut (Koh et al. 2008; Papon, Bougnoux and d Enfert
2020). Once in the blood, C. albicans can disseminate to almost
all organs including kidney, liver, and spleen (Pappas et al. 2018).
The mortality rate for these infections, which varies across geo-
graphical regions, is reported to lie between 10% and 47% despite
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Figure 2. Sites of C. albicans commensalism and disease on the human body. Sites of C. albicans commensalism (left side) include the oral cavity, gastrointestinal tract
(gut) and the genital tract. C. albicans can infect these sites (right side) to cause oropharyngeal or vulvovaginal candidiasis. C. albicans can also cause systemic infections
of the blood and internal organs, which often arise via translocation of C. albicans from the gut into the bloodstream. Candida albicans also causes mucocutaneous
infections of the skin and nails. Factors that predispose individuals to such infections are listed. See text.
Clearly, knowledge about the factors and conditions that pro-
mote C. albicans commensalism or opportunism is important for
an understanding of the mechanisms that underlie the tran-
sition from commensalism to pathogenicity. Much work has
focussed on the virulence factors and fitness attributes that
promote C. albicans infection (see Virulence Factors and Fitness
attributes). However, the pathogenesis of C. albicans also depends
on the host site of colonisation (Fidel et al. 2020). Candida albi-
cans asymptomatically inhabits the oral mucosa and only causes
infection when host defences are weakened. In contrast, C. albi-
cans is an immunoreactive coloniser during vulvovaginal infec-
tion, eliciting host damage via a hyperactive immune response.
Meanwhile, systemic infections are mostly nosocomial and are
generally associated with predisposing conditions. The fungus
is able to cause these different types of infection by tuning
the expression of its arsenal of virulence factors and fitness
attributes to the local niche.
Virulence factors
Cellular polymorphism
The polymorphic nature of C. albicans is integral to both com-
mensalism and pathogenesis. This fungus is able to switch
reversibly between different growth forms and morphologies
(Noble, Gianetti and Witchley 2017) (Fig. 3). Depending upon
the environmental conditions, C. albicans can grow as unicellu-
lar yeast cells, pseudohyphae, or true hyphae that lack invagi-
nations at septal junctions (Sudbery, Gow and Berman 2004).
Also, depending on the presence of certain environmental cues,
C. albicans can undergo phenotypic switching to interchange
reversibly between white, grey and opaque phenotypes, each
of which displays distinct yeast cell and colony morphologies,
and gene expression profiles. Furthermore, a gastrointestinally
induced transition (GUT) phenotype has been described for C.
albicans cells that ectopically overexpress the Wor1 regulator
which, together with Efg1, controls white-grey-opaque switch-
ing (Pande, Chen and Noble 2013). Phenotypic switching is a
strictly regulated process that seems to be associated with com-
mensalism, host niche adaptation, mating, immune evasion and
virulence (Miller and Johnson 2002; Morschhäuser 2010; Pande,
Chen and Noble 2013; Xie et al. 2013; Tao et al. 2014). Finally,
C. albicans can differentiate to form chlamydospores, enlarged
thick-walled cells, under nutrient limitation, low temperature
and microaerophilia (Staib and Morschhäuser 2007; Böttcher
et al. 2016) (Fig. 3).
Both yeast and hyphal morphologies are necessary for the
full virulence of C. albicans (Lo et al. 1997; Murad et al. 2001; Sav-
ille et al. 2003; Jacobsen et al. 2012) (Fig. 4). However, it is gen-
erally thought that yeast cells are well suited to dissemination,
and hyphal cells to tissue invasion (Gow, Brown and Odds 2002).
The yeast-to-hypha transition is accompanied by an extensive
change in gene expression profile, in cell wall structure, and by
the expression of many virulence factors (Jacobsen et al. 2012;
Mayer, Wilson and Hube 2013; Chen et al. 2020). The change
in morphology can be triggered by many environmental fac-
tors present in host niches, such as physiological temperatures
(>36◦C), starvation, an ambient pH of >7, the presence of serum,
N-acetylglucosamine, or elevated CO2 levels (Mayer, Wilson and
Hube 2013). Furthermore, hyphal development is triggered by
the bacterial cell wall component, peptidoglycan (Xu et al. 2008),
which is of particular relevance to fungus-host-microbiota inter-







sre/article/45/3/fuaa060/6000215 by guest on 25 Septem
ber 2021
d’Enfert et al. 5
Figure 3. Candida albicans is polymorphic, displaying a range of cellular growth forms. C. albicans yeast cells can undergo phenotypic switching between white, grey
and opaque growth forms that present with different shapes and cell surface characteristics (Gow, Brown and Odds 2002; Sudbery, Gow and Berman 2004; Xu et al.
2008; Huang et al. 2009; Mayer, Wilson and Hube 2013; Tao et al. 2014; Sun et al. 2015). These forms are induced in response to different environmental inputs, and
hence are associated with different types of infection (Gow, Brown and Odds 2002). Significantly, the opaque form is associated with efficient mating in C. albicans
(Miller and Johnson 2002), with grey cells displaying an intermediate mating competence between opaque and white cells (Tao et al. 2014). The gastrointestinally
induced transition (GUT) phenotype is observed in C. albicans cells that ectopically express WOR1 (Pande, Chen and Noble 2013), a key regulator of commensalism. The
transition from (white) yeast cells to pseudohyphae or hyphae is stimulated by a wide variety of environmental inputs, which include elevated temperatures, pH and
peptidoglycan. Pseudohyphae can be distinguished from hyphae on the basis of the position of the septal junction between a mother yeast cell and its filamentous
daughter, and by the presence of invaginations at these septal junctions in pseudohyphae, but not hyphae (Merson-Davies and Odds 1989; Sudbery 2001; Sudbery, Gow
and Berman 2004). Candida albicans can be induced to form chlamydospores under specific environmental conditions (Jansons and Nickerson 1970), but the biological
significance of this growth form remains obscure (Staib and Morschhäuser 2007). See text.
inputs and cellular outputs, yeast-hypha morphogenesis is reg-
ulated by a complex signalling network that includes the cAMP-
protein kinase A, Efg1, Cph1, Czf1, Hog1 and Nrg1 pathways
(Basso et al. 2019; Kadosh 2019; Kornitzer 2019).
During experimental colonisation of the murine GI tract, C.
albicans was found to thrive in the yeast form (Vautier et al. 2015).
The basis for the predominance of the yeast morphology during
gut colonisation remains unclear, but unknown selective pres-
sures favour growth in the yeast form during experimental GI
colonisation in mice during GI dysbiosis (Tso et al. 2018). Further-
more, mucus covering the epithelium, tight junctions between
epithelial cells, and the lamina propria serve as physical barri-
ers that limit C. albicans translocation and dissemination from
the gut (Yan, Yang and Tang 2013; Arevalo and Nobile 2020).
Mucin, the main component of mucus, prevents hyphal forma-
tion (Kavanaugh et al. 2014) and reduces the adherence of C. albi-
cans to epithelial cells (de Repentigny et al. 2000). Similarly, saliva
can exert anti-Candida effects in the oral cavity (Hibino et al.
2009) (see Oral cavity). More recent work suggests that filamen-
tous forms can exist in certain parts of the GI tract where the
microenvironment favours hyphal development (Witchley et al.
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Figure 4. A combination of virulence factors and fitness attributes promote C. albicans virulence. Polymorphism: The ability of C. albicans to undergo morphological
transitions allows it to adapt to different growth conditions, adhere to biotic and abiotic surfaces, invade cells and tissue, and escape from immune cells. Invasion and
damage: A combination of induced endocytosis and active penetration promote fungal invasion of host tissues, and the accumulation of the toxin, candidalysin, in the
invasion pocket leads to pore formation and host cell damage. Adhesion/biofilm formation: The battery of adhesins promotes fungal adhesions to biological and abiotic
surfaces, which can lead to the development of biofilms, for example on medical devices such as catheters. Genetic and metabolic plasticity: Candida albicans displays
a high degree of metabolic flexibility, which allows it to adapt rapidly to diverse host niches. This fungus also displays great genetic plasticity, which permits rapid
evolutionary adaptation to selective pressures and stresses such as exposure to antifungal drugs. Stress responses: Candida albicans activates robust stress responses
following exposure to host imposed stresses, including ROS and RNS, which enhances fungal survival following immune attack, for example. Cell wall: As well as
maintaining cell morphology, the robust cell wall provides protection against host-imposed stresses including changes in osmolarity. Immune evasion: Candida albicans
has evolved a variety of immune evasion strategies that include the modulation of PAMP exposure at the cell surface to evade immune recognition, and phagocytic
escape mechanisms to evade killing by innate immune cells. See text.
perturbed microbiota and a compromised immune system lose
control over C. albicans growth (see The Host and The Microbiota),
the fungus can switch from commensalism to pathogenicity
(Gow et al. 2011).
Significantly, the host can exploit the yeast-to-hypha tran-
sition to discriminate between colonisation and infection. This
involves a biphasic innate immune response at the epithe-
lial barrier (Moyes et al. 2010; Roselletti et al. 2019). The first
signalling event is triggered by fungal cell wall components,
notably β-glucans and mannans, irrespective of cell morphology
(Moyes et al. 2010). The second, danger response, is only induced
once a high fungal burden is achieved, hypha formation occurs,
and the hypha-associated toxin candidalysin is expressed (see
Host damage) (Moyes et al. 2010, 2016). This leads to the secretion
of pro-inflammatory cytokines and phagocyte infiltration, which
promote fungal clearance. In addition, phagocytes can distin-
guish hyphae from yeast cells based on the shorter cell wall
mannan fibrils of hyphal cells (Cheng et al. 2011). Macrophages
also respond to hyphal load, in part through the degree of
metabolic competition between host and pathogen, displaying
reduced activation of the NLRP3-inflammasome pathway at low
hyphal burdens (Tucey et al. 2020; Westman et al. 2020). Thus,
while hypha formation is critical for invasion (see Invasion mech-
anisms), the host has developed mechanisms to recognise the
invasive form of C. albicans. Therefore, hypha formation seems
to be detrimental for C. albicans commensalism.
Adhesion to abiotic and biotic surfaces
Candida albicans cells can adhere to each other as well as to host
cells and abiotic surfaces, such as catheters or dental implants,
which promotes colonisation and the formation of biofilms (de
Groot et al. 2013; Lohse et al. 2018) (Fig. 4). Candida albicans forms
hyphae upon sensing contact to a surface (Kumamoto 2008) and
hyphae express specific adhesins that promote adhesion to such
surfaces (de Groot et al. 2013).
The Agglutinin-Like Sequence (ALS) genes represent one
family of adhesins in C. albicans, some of which are morpho-
genetically regulated (Hoyer and Cota 2016). Analogous adhesin
families are present in other pathogenic and non-pathogenic
fungi (Butler et al. 2009). Als adhesins have a three-domain struc-
ture: the N-terminal ligand-binding domain (Lin et al. 2014);
internal tandem repeats; and the C-terminal domain, which
binds the cell wall via a modified glycosylphosphatidylinisotol
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bers, each of which displays a high degree of variability between
alleles and strains, particularly in the length of the central repet-
itive domain (Hoyer and Cota 2016). Als3, the best-studied Als
family member, has multiple functions. It binds heterogenous
ligands including cadherins, ferritin and a Streptococcus gordonii
surface protein (Phan et al. 2007; Almeida et al. 2008; Bamford
et al. 2015). Als3 also acts as an invasin that promotes fungal
invasion of host cells (Phan et al. 2007) and iron assimilation
(Almeida et al. 2008). This makes Als3 an asset for the fungus
during infection, but also a potential target for anti-Candida ther-
apies (Edwards et al. 2018; Marc et al. 2018; Kioshima et al. 2019).
The hyphal wall protein 1 (Hwp1), is specifically expressed
during hyphal growth (Staab, Ferrer and Sundstrom 1996),
and is the founding member of a second family of five
adhesins in C. albicans (de Groot et al. 2013). Members of
the Hwp family are required for both virulence and mating.
The N-terminus of Hwp1 is enriched in glutamine residues
that become cross-linked to the host extracellular matrix by
host transglutaminases (Staab et al. 1999). In contrast, Yeast
wall protein 1 (Ywp1) appears to counteract adhesion lead-
ing to the release of yeast cells from surfaces, which might
promote fungal dissemination during systemic candidiasis
(Granger 2012).
A third family of putative adhesins is encoded by the twelve-
member HYR gene family (de Groot et al. 2013). The founding
member of this family, HYR1, like ALS3 and HWP1, is expressed
during hyphal development (Bailey et al. 1996). This HYR family
has been less well characterised than the ALS and HWP families.
Nevertheless, it adds to the adhesins that C. albicans expresses
to promote robust adhesion to each other, abiotic surfaces or the
host.
The cell wall
Both cellular polymorphism and adhesion are intimately asso-
ciated with the C. albicans cell wall, the organelle that maintains
the morphology of the C. albicans cell and that supplies the scaf-
fold for most adhesin proteins (Klis, de Groot and Hellingwerf
2001; de Groot et al. 2004; Gow, Latge and Munro 2017) (Fig. 4).
The cell wall also provides osmotic stability and protects against
environmental stresses. It is robust in exerting control of cell
shape, and yet elastic during responses to acute osmotic stress
(Ene et al. 2015). Furthermore, the cell wall is a highly flexi-
ble organelle, in that it displays a high capacity to adapt and
remodel itself in response to environmental challenges or anti-
fungal drugs (Sosinska et al. 2008; Ene et al. 2012; Childers et al.
2019).
The C. albicans cell wall is a two-layered structure. The inner
layer consists of chitin, β-1,3- and β-1,6-glucans and manno-
proteins. The outer layer is enriched in mannan fibrils that are
anchored to mannoproteins cross-linked to the inner layer of
the wall (Kapteyn et al. 2000; Gow et al. 2011; Gow, Latge and
Munro 2017). Chitin comprises about 2%–3% of the mass of the
yeast cell wall, but represents an important structural compo-
nent that is essential for the integrity of the cell wall. The main
structural polysaccharide of the C. albicans cell wall is β-glucan,
which accounts for 50%–60% of the mass of the yeast cell wall
(Shepherd 1987; Klis, de Groot and Hellingwerf 2001). The β-1,3-
glucan network provides the platform for covalent attachment
of chitin, β-1,6-glucan and mannoproteins.
Two main classes of cell wall mannoproteins have been
defined in C. albicans. GPI-anchored proteins are the more abun-
dant class. As their name suggests, these are linked via modi-
fied GPI anchors to β-1,6-glucan which, in turn, are covalently
attached to β-1,3-glucan (Kapteyn et al. 2000). Pir proteins (pro-
teins with internal repeats) are covalently attached to β-1,3-
glucan directly (Kapteyn et al. 2000). C. albicans cell wall manno-
proteins contribute 30–40% of the mass of the yeast cell wall
(Kapteyn et al. 2000) and are adorned with N- and/or O-linked
oligosaccharides. The O-linked oligosaccharides are often linked
to serine-threonine-rich repeats (e.g. in ALS adhesins: see Adhe-
sion to abiotic and biotic surfaces) and are thought to confer rod-
like structures to these domains (Gatti et al. 1994). N-linked man-
nans are highly branched structures that form the fibrils in the
outer layer of the wall (Gow, Latge and Munro 2017; Childers et al.
2019). The functions of about 70% of cell wall mannoproteins
remain obscure, but some are known or suspected to be involved
in the infection process (De Groot, Ram and Klis 2005; Richard
and Plaine 2007).
The cell wall is an attractive target for antifungal therapy
because it is essential for fungal viability and not present on
human cells. Consequently, β-1,3-glucan synthesis is the tar-
get for a major class of antifungal drugs in clinical use—the
echinocandins (Odds, Brown and Gow 2003). Significantly, in the
context of this review, the cell wall is also the first point of direct
contact with the host, and therefore a prime target for immune
recognition (see Fungal recognition) (Netea et al. 2008; Erwig and
Gow 2016).
Biofilm formation
Candida albicans can form florid biofilms on biological surfaces
and also abiotic surfaces such as catheters, dentures and pros-
thetic joints (Fig. 4). Biofilms are a common source of nosocomial
infection (Ramage et al. 2005; Nobile and Johnson 2015), and they
increase therapeutic challenges by enhancing the resistance to
antifungal drugs (Taff et al. 2013).
Biofilm formation is initiated by adhesion of C. albicans cells
to the surface (see Adhesion to abiotic and biotic surfaces). Surface
contact stimulates hyphal growth (see Cellular polymorphism), the
development of the biofilm and the production of extracellular
matrix, and the biofilm matures into an organised and robust
structure (Nobile and Johnson 2015). Biofilm formation is a com-
plex process that is controlled by a network of transcription
factors and that integrates the expression of adhesins, cellu-
lar morphogenesis and the production of extracellular matrix.
Accordingly, biofilm formation is controlled by a complex tran-
scriptional network of over 1000 genes (Finkel and Mitchell 2011;
Nobile et al. 2012; Lohse et al. 2018). These target genes include
members of the ALS family, which are essential for biofilm for-
mation and enhance aggregation between fungal cells via amy-
loid formation (Dehullu et al. 2019; Vida Ho et al. 2019).
Biofilm maturation is followed by the dispersal of yeast cells
from the biofilm, which promotes fungal dissemination. Candida
albicans cells dispersed from biofilms are distinct from plank-
tonically grown yeast. These dispersed cells are transcription-
ally reprogrammed to utilise alternative carbon sources and they
acquire nutrients, such as zinc and amino acids, with higher effi-
ciency (Uppuluri et al. 2018).
Candida albicans clinical isolates display a high degree of het-
erogeneity with respect to their capacity to form biofilms and
the underlying regulatory network (Sherry et al. 2017; Huang et al.
2019), and biofilm-forming ability has been associated with high
mortality rates in patients (Rajendran et al. 2016). In the clini-
cal setting, the situation is further complicated by the forma-
tion of multispecies biofilms. For example, C. albicans is com-
monly associated with Streptococcus and Actinomyces species in
dental samples, with Lactobacillus species in vaginal specimens,
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(Hogan, Vik and Kolter 2004; Falagas, Betsi and Athanasiou 2006;
Bamford et al. 2009; Bandara et al. 2009; Cruz et al. 2013; Bam-
ford et al. 2015) (see Synergistic and antagonistic interactions between
kingdoms). These inter-kingdom associations affect C. albicans
growth, morphogenesis and drug resistance (Hogan, Vik and
Kolter 2004).
Invasion mechanisms
The invasion of host cells and tissues provides an effective
strategy to access more nutrients, avoid competition with other
members of the microbiota, and potentially escape antimicro-
bial treatment (Fig. 4). Two distinct routes for the invasion of
epithelia and endothelia are known for C. albicans: induced
endocytosis and active penetration (Dalle et al. 2010; Wächtler
et al. 2012). Induced endocytosis is mediated by the fungal pro-
teins Ssa1 and Als3 (the adhesin-invasin, mentioned above),
both of which are present on the cell wall. These proteins bind to
E- and N- cadherins on epithelial and endothelial cells, as well as
to the epithelial growth factor receptor of oral epithelial cells, to
induce the uptake of fungal cells through remodelling of the host
cytoskeleton (Phan et al. 2007; Moreno-Ruiz et al. 2009; Sun et al.
2010; Solis et al. 2017). Active penetration is achieved through the
growth of hyphae into host tissue. This is the dominant route of
fungal invasion into oral epithelial cells and the only observed
route in enterocytes (Dalle et al. 2010; Wächtler et al. 2012).
As stated, the GI tract is a major reservoir for resident C.
albicans (Nucci and Anaissie 2001; Gouba and Drancourt 2015),
and hence fungal translocation across intestinal barriers is a
common source of systemic candidiasis. This translocation can
be promoted by injury, GI pathologies or medical interventions.
Nevertheless, the translocation of C. albicans cells through ente-
rocytes in a transcellular manner, and subsequent necrotic host
cell death, is a major mechanism by which the fungus crosses
the epithelial barrier (Allert et al. 2018). C. albicans directs physi-
cal force against cell membranes to stretch and rupture host cell
membranes via a combination of hyphal growth and secreted
virulence factors (Wächtler et al. 2012). Meanwhile, host cells
employ several mechanisms to expand and repair membranes
to limit this damage (Westman, Hube and Fairn 2019). This leads
to the formation of the so-called ‘invasion pocket’ where the
invading hypha is surrounded by host membrane (Moyes et al.
2016). The confined space around the hypha, within the inva-
sion pocket, permits the accumulation of C. albicans secreted
virulence factors to high local concentrations that cause further
damage and stress to the host (Dalle et al. 2010; Moyes et al. 2016;
Allert et al. 2018).
Host damage
The ability to damage host cells provides C. albicans with access
to cytoplasmic nutrients, and the fungus possesses an exten-
sive weaponry to impose damage (Fig. 4). Damaging factors that
accumulate in the invasion pocket include secreted hydrolases
such as phospholipase B1, lipases and secreted aspartic pro-
teases (Saps) that degrade host membranes, proteins and extra-
cellular matrix releasing nutrients (Mukherjee et al. 2001; Naglik,
Challacombe and Hube 2003; Schofield et al. 2005). Candida albi-
cans also expresses candidalysin—a pore forming α-helical pep-
tide toxin that is encoded by the ECE1 gene (Moyes et al. 2016).
Pores formed in the host cell membrane by candidalysin proba-
bly leak cytoplasmic contents into the invasion pocket, thereby
providing additional nutrients for the fungus. This may include
access to essential micronutrients such as iron and zinc. Spe-
cific proteins bind these micronutrients, which are then endo-
cytosed or transported across the fungal cell membrane via
specific transporters. For example, members of the Rbt5-family
transport heme across the cell wall (Kuznets et al. 2014; Nasser
et al. 2016). Also, zinc is acquired via the zincophore Pra1 (pH-
regulated antigen 1), which is released into the extracellular
space and then, when loaded with zinc, is transported back into
the fungus by the zinc transporter Ztr1 (Citiulo et al. 2012).
Fitness attributes
Fitness attributes are factors that promote fungal virulence by
enhancing the physiological robustness of the fungus in host
niches, rather than by interacting directly with the host. In C.
albicans, fitness attributes include metabolic flexibility combined
with potent nutrient acquisition systems, and robust stress
response mechanisms (Mayer, Wilson and Hube 2013; Brown,
Budge et al. 2014; Brown, Brown, et al. 2014). These promote the
success of C. albicans both as a commensal and as a pathogen of
humans.
Flexible metabolic adaptation
Metabolic adaptability is critical during C. albicans transitions
between commensalism and pathogenicity (Fig. 4). This was
highlighted by an elegant screen for regulatory circuitry that
drives the commensal and pathogenic states in C. albicans (Pérez,
Kumamoto and Johnson 2013). Much of this circuitry is involved
in the regulation of metabolism. Metabolic regulation in C. albi-
cans is integrated with the control of virulence factors and stress
resistance through major regulatory hubs such as Efg1, Tup1,
Nrg1, Hog1 and Gcn4 (Murad et al. 2001; Tripathi et al. 2002; Doedt
et al. 2004; Alonso-Monge et al. 2009). Therefore, metabolic adap-
tation is essential for commensalism and virulence, and is inti-
mately linked with other pathogenicity traits (Mayer, Wilson and
Hube 2013; Brown, Brown, et al. 2014).
Glucose is a preferred carbon source for C. albicans, but under
glucose-limiting conditions, such as in the colon or after entrap-
ment in the phagosome, C. albicans tunes its metabolism to feed
on alternative carbon sources (Lorenz, Bender and Fink 2004;
Barelle et al. 2006). Even when glucose becomes available, C.
albicans can simultaneously utilise alternative carbon sources
through multiple pathways (Sandai et al. 2012; Childers et al.
2016). This metabolic flexibility allows the fungus to adapt to
contrasting host niches. Significantly, it also influences the tol-
erance of C. albicans to antifungal drugs and environmental
stresses (Ene et al. 2012). For example, growth on lactate protects
against osmotic and cell wall stresses while utilisation of amino
acids and N-acetylglucosamine (GlcNAc) increases fungal resis-
tance to reactive oxygen and nitrogen species (ROS and RNS,
respectively) (Williams and Lorenz 2020). These alternative car-
bon sources appear to serve as niche-specific signals that prime
the fungus for impending challenges, pointing to the dexterity
of C. albicans not only to adapt, but also to anticipate, local stress
conditions (Brown, Budge et al. 2014; Alistair J P Brown et al. 2019;
Williams and Lorenz 2020). The metabolic flexibility of C. albi-
cans extends well beyond carbon metabolism to include nitro-
gen, phosphate and micronutrient assimilation (Lorenz, Bender
and Fink 2004; Yin et al. 2004; Vylkova et al. 2011; Ene et al. 2014;
Ikeh et al. 2016).
Micronutrients, such as iron and zinc, are essential for
structural integrity and physiological processes in C. albicans.
However, in response to infection, through a process called
nutritional immunity, the host limits the availability of these
micronutrients and exposes the fungus to toxic levels of other
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Mackie et al. 2016; Sprenger et al. 2018). In response, the fun-
gus activates efficient micronutrient acquisition strategies. High
affinity iron uptake involving a cyclic iron reduction pathway
(iron reductase, multicopper ferroxidase and iron permease)
is activated to take over from low affinity ferritin-iron uptake
via the protein Als3, which is operational in hyphae during
iron-replete conditions (Wilson, Naglik and Hube 2016; Bairwa,
Hee Jung and Kronstad 2017). Candida albicans can also assim-
ilate iron from heme and hemoglobin using Common in Fun-
gal Extracellular Membrane (CFEM) proteins, and can scavenge
siderophores synthesised by other microorganisms using the
Arn1/Sit1 ferrichrome transporter (Bairwa, Hee Jung and Kro-
nstad 2017). Transcriptional circuitry involving Sef1, Sfu1 and
Hap43 control iron homeostasis by activating iron assimila-
tion mechanisms when iron is limiting, and by repressing iron
uptake when it is in excess (Chen et al. 2011; Noble 2013). Can-
dida albicans utilises two uptake mechanisms to scavenge zinc.
The first, which operates mainly at acidic pHs, involves uptake
via the Zrt2 transporter into the cytoplasm (Crawford et al.
2018). The second, which is functional at neutral pHs, entails
zincophore-mediated zinc scavenging through a secreted pro-
tein, Pra1 and uptake via the transporter Zrt1 (Citiulo et al. 2012;
Wilson 2015; Crawford et al. 2018). C. albicans responds to zinc
limitation by forming goliath cells (enlarged and spherical yeasts
that exhibit enhanced adhesion) and avoids zinc toxicity by
rapidly compartmentalizing zinc in storage vacuoles called zin-
cosomes (Malavia et al. 2017; Crawford et al. 2018).
Robust stress responses
Fungal pathogens generally display robust responses to cer-
tain stresses, particularly oxidative stress (Brown et al. 2017)
(Fig. 4). Candida albicans is resistant to significantly higher levels
of ROS than its distant cousin, Saccharomyces cerevisiae (Jamieson,
Stephen and Terrière 1996; Nikolaou et al. 2009) and this helps
the fungus to counter toxic ROS produced by innate immune
cells, before and during phagocytic attack (Miramón et al. 2012).
C. albicans and other fungal pathogens counteract acute exoge-
nous oxidative stresses by inducing genes involved in ROS
detoxification (e.g. catalase and superoxide dismutases), the
synthesis of antioxidants (e.g. glutathione and thioredoxin),
and the repair of ROS-mediated damage to DNA, proteins and
lipids (Enjalbert, Nantel and Whiteway 2003, Enjalbert et al.
2006; Znaidi et al. 2009). The inactivation of key regulators of
the response in C. albicans (Cap1, Skn7 and Hog1) compromises
oxidative stress resistance (Alarco and Raymond 1999; Singh
et al. 2004; Smith et al. 2004). Virulence is attenuated by the
inactivation of the Hog1 stress activated protein kinase (Alonso-
Monge et al. 1999; Cheetham et al. 2011), but only to a minor
extent by the loss of Cap1 or Skn7 (Singh et al. 2004; Jain et al.
2013). The overexpression of catalase, which detoxifies hydrogen
peroxide, enhances oxidative stress resistance in vitro, and yet,
counterintuitively, reduces the virulence of C. albicans (Román
et al. 2016; Pradhan et al. 2017). This is because overexpres-
sion of this abundant ferroprotein places an undue demand for
the essential micronutrient, iron, under iron limiting conditions
in vivo (Pradhan et al. 2017). Clearly, numerous and potentially
opposing, selective pressures must be balanced to optimise fun-
gal fitness in a particular host niche.
While much attention has focussed on oxidative stress,
C. albicans faces other forms of environmental stress in the
host, including nitrosative, osmotic and thermal stresses. Innate
immune cells expose C. albicans to RNS) in an attempt to kill
and clear the fungus. C. albicans responds by activating genes
involved in RNS detoxification (such as the flavohemoglobin,
Yhb1), glutathione synthesis and recycling, and the repair of
RNS-mediated damage (Hromatka, Noble and Johnson 2005; Till-
mann et al. 2015). The response to nitrosative stress is driven by
the transcription factor Cta4 and Hog1 (Chiranand et al. 2008;
Herrero-de-Dios et al. 2018). The inactivation of YHB1, CTA4
or HOG1 attenuates nitrosative stress resistance and virulence
(Alonso-Monge et al. 1999; Hromatka, Noble and Johnson 2005;
Chiranand et al. 2008; Cheetham et al. 2011; Miramón et al. 2012).
Candida albicans cells thrive in niches with different osmo-
larities (e.g. on skin, in the oral cavity or GI tract), and yet must
maintain osmo-homeostasis to grow. Hypo- and hyper-osmotic
challenges are countered by modulating the levels of intracel-
lular osmolytes. For example, C. albicans upregulates the syn-
thesis and accumulation of glycerol and arabitol in response
to hyperosmotic challenges (San José et al. 1996; Kayingo and
Wong 2005). This response is regulated at both transcriptional
and post-transcriptional levels by the evolutionarily conserved
Hog1 MAP kinase signalling pathway (Smith et al. 2004; Enjalbert
et al. 2006).
Candida albicans must also restore and maintain proteostasis
in the face of thermal challenges, even within the mammalian
host (Nicholls et al. 2011). Even mild increases in temperature
lead to activation of the so-called heat shock response (Leach,
Tyc et al. 2012), which is regulated by an autoregulatory circuit
involving the heat shock transcription factor (Hsf1) and heat
shock protein 90 (Hsp90) (Leach, Budge et al. 2012). The response
involves the induction of functions involved in protein refolding
and protein degradation to repair or recycle damaged proteins
(Nicholls et al. 2009; Leach et al. 2016). The heat shock response
is integrated with key virulence attributes in C. albicans such as
yeast-hypha morphogenesis, adhesion and the ability to dam-
age epithelial cells (Shapiro et al. 2009; Leach et al. 2016). Con-
sequently, the inactivation of the response attenuates virulence
(Nicholls et al. 2011).
Candida albicans can thrive over an extremely wide range of
ambient pHs, from pH 2 to 10 (Vylkova et al. 2011). pH responses
are particularly relevant given the ability of C. albicans to colonise
host niches with contrasting pHs such as the vagina (acidic), GI
tract (acidic to mildly alkaline) and blood (neutral). These pH
responses, which are regulated in part by the evolutionarily con-
served Rim101 pathway (Davis, Wilson and Mitchell 2000), are
tightly integrated with metabolic adaptation, nutrient acquisi-
tion and morphogenesis (Davis et al. 2000). Yeast-hypha mor-
phogenesis in C. albicans is regulated in response to ambient pH
(Buffo, Herman and Soll 1984; Porta et al. 1999; Chen et al. 2020;
Villa et al. 2020). Ambient pH also affects trace metal solubil-
ity, and consequently, micronutrient assimilation strategies in
C. albicans are regulated in response to pH (Noble 2013; Wilson
2015; Crawford et al. 2018). Significantly, C. albicans is not sim-
ply reactive to pH: it can proactively alkalinise its microenviron-
ment through the catabolism of polyamines and amino acids,
leading to the release of ammonia and/or CO2 (Mayer et al. 2012;
Vylkova and Lorenz 2014; Danhof et al. 2016; Vylkova 2017). Inter-
estingly, lactate production by a co-commensal in the oral cavity,
Streptococcus mutans, provides carboxylic acid substrates that are
sufficient to promote C. albicans-mediated alkalinisation of the
microenvironment (Danhof et al. 2016; Willems et al. 2016).
Immune evasion
Immune evasion can be viewed as an additional type of fitness
attribute because it promotes the physiological robustness of
the fungus in the host (Fig. 4). Candida albicans has evolved a
variety of mechanisms through which it can reduce recognition
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mechanisms, escape immune cells following engulfment, and
manipulate the immune system (see Innate antifungal responses
and Fungal countermeasures for more detail). During co-evolution
with its host, C. albicans has even developed mechanisms by
which it can anticipate, and protect itself against, imminent
immune attack.
Clearly, C. albicans possesses an array of powerful fitness
attributes through which this fungus tunes its physiology to
counter environmental challenges presented by the host. Sig-
nificantly, the fungus not only adapts to host-defined conditions,
but can also anticipate impending challenges, and actively mod-
ulate its microenvironment.
Candida albicans epidemiology and variability
The flexibility of C. albicans, which underlies its success as a
commensal and a pathogen, is also reflected at the genetic level
(Fig. 4). Clinical isolates of C. albicans are generally diploid, with
a haploid genome size of 16 Mb, organised into eight chro-
mosomes. However, isolates display high levels of sequence
heterozygosity between homologous chromosomes (Selmecki,
Forche and Berman 2006; Ford et al. 2014; Hirakawa et al. 2015)
and a high degree of genome plasticity driven by ploidy changes,
karyotypic variations due to partial and whole chromosome
aneuploidies, point mutations, short and long-range loss of het-
erozygosity (LOH) events and copy number variations (Chibana,
Beckerman and Magee 2000; Selmecki, Forche and Berman 2006;
Ford et al. 2014; Hirakawa et al. 2015; Ropars et al. 2018; Sitterlé
et al. 2019). Furthermore, haploid and tetraploid strains have
been observed both in vitro and in vivo (Hull, Raisner and Johnson
2000; Magee and Magee 2000; Hickman et al. 2013).
Multilocus sequence typing (MLST) and genome sequencing
studies have revealed that C. albicans isolates are distributed
amongst at least 23 genetic clusters (1–18, A-E) (Bougnoux et al.
2006; Odds et al. 2007; Odds 2010; Ropars et al. 2018). In general,
there are no clear phenotypic associations with these clusters
(Bougnoux et al. 2006; MacCallum et al. 2009). However, some
clusters do exhibit geographical enrichment (Odds et al. 2007;
MacCallum et al. 2009; Shin et al. 2011), suggesting indepen-
dent recent evolutionary histories for these clusters. Cluster 13
is somewhat exceptional in that it represents a highly clonal
lineage of isolates that exhibit low heterozygosity (Ropars et al.
2018). Isolates in cluster 13 are distributed worldwide (Fakhim
et al. 2020), despite being called Candida africana strains (Tietz
et al. 2001). They are isolated predominantly from the genital
niche and display unusual morphological and phenotypic fea-
tures that include slow growth, an inability to produce chlamy-
dospores and assimilate aminosugars, and decreased virulence
(Tietz et al. 2001; Romeo, De Leo and Criseo 2011; Borman et al.
2013). In contrast to other C. albicans clusters, cluster 13 isolates
harbour a unique pattern of single nucleotide polymorphisms
(SNPs) and a significantly lower level of heterozygosity (Ropars
et al. 2018). In addition, in cluster 13 isolates, genes important
for morphogenesis and virulence have undergone pseudogeni-
sation, which probably explains the decreased virulence and
apparent genital niche restriction of these isolates (Ropars et al.
2018).
Once thought to be an asexual obligate diploid organism, C.
albicans has been shown to undergo a parasexual cycle (Magee
and Magee 2000; Bennett and Johnson 2003; Ene and Bennett
2014). The majority of C. albicans diploid strains are incapable
of mating, being heterozygous at the mating type-like (MTL)
locus. However, mating can occur mainly between strains that
have become homozygous at the MTL locus on chromosome 5,
and have complementary MTL genotypes (i.e. are MTLa/a and
MTLα/α). Additionally, mating in C. albicans is also dependent
on a phenotypic switch from the mainly sterile ‘white’ pheno-
type to the mating competent ‘opaque’ phenotype (Miller and
Johnson 2002). Mating between competent isolates of opposite
mating-type results in tetraploid cells. These can subsequently
undergo concerted chromosome loss, which can restore the
diploid state in a meiosis-independent manner (Bennett and
Johnson 2003; Hickman et al. 2015). However, this process yields
diverse intermediate aneuploid states (Hickman et al. 2015).
Hence, this mode of parasexual reproduction provides a means
of generating genetic and phenotypic diversity in C. albicans
(Forche et al. 2008; Hickman et al. 2015). Indeed, recombination
has been shown to occur three orders of magnitude more fre-
quently during concerted chromosome loss than during mitosis
(Anderson et al. 2019). Interestingly, recombination during con-
certed chromosome loss is highly dependent on two meiosis-
specific genes, SPO11 and REC8 (Forche et al. 2008; Anderson et al.
2019). The involvement of meiosis-specific genes in concerted
chromosome loss has led to the suggestion that this process
‘blurs the boundaries’ between meiosis and mitosis, and that this
‘parameiosis’ might provide insight into the evolution of meiosis
(Anderson et al. 2019).
The view that the parasexual cycle rarely occurs in the host
is supported by population genetics, which shows that C. albi-
cans populations are predominantly clonal (Pujol et al. 1993;
McManus and Coleman 2014). Nevertheless, the conservation
of mating genes suggests that this process is associated with
an evolutionary advantage. Furthermore, because the parasex-
ual cycle is stimulated by environmental stress, it may be a
diversity-enhancing process that enhances adaptation and sur-
vival under hostile conditions (Selmecki, Forche and Berman
2010; Zhang et al. 2015; Hirakawa et al. 2017; Popp et al. 2019). This
idea is corroborated by evidence of recombination and gene flow
in natural isolates, despite the largely clonal structures of C. albi-
cans populations (Odds et al. 2007; Bougnoux et al. 2008; Zhang
et al. 2015; Ropars et al. 2018). This could explain why C. albicans
isolates maintain a high degree of genetic diversity despite their
predominantly clonal reproduction.
The diversity of C. albicans populations has arisen partly
through changes in ploidy and aneuploidy. These mechanisms
have provided C. albicans with a means of evolving rapidly in
response to environmental challenges (Selmecki, Forche and
Berman 2006; Diogo et al. 2009; Bennett, Forche and Berman
2014). The association of genome rearrangements with anti-
fungal resistance acquisition has been well documented, with
genomes of antifungal-resistant strains often exhibiting copy
number variations and chromosome aneuploidies (Selmecki,
Forche and Berman 2010). Indeed, a striking example of seg-
mental aneuploidy was reported in fluconazole resistant strains,
consisting of an isochromosome composed of the two left arms
of chromosome 5 (Selmecki, Forche and Berman 2006, Selmecki
et al. 2008). Trisomy of chromosome 2 or R has also been reported
to enhance antifungal drug resistance in C. albicans (Xingxing Li
et al. 2015; Yang et al. 2019). Large-scale chromosome rearrange-
ments occur in C. albicans as an adaptation mechanism in both
oral and GI niches (Ene et al. 2018; Forche et al. 2018). Similar
observations have been made in isolates collected from a sin-
gle human individual (Sitterlé et al. 2019). Genome sequencing
of clinical isolates from patients that received antifungal ther-
apy revealed that eight of the 21 isolates underwent karyotypic
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7 (Hirakawa et al. 2015). However, a more recent study of 182 clin-
ical isolates might suggest that both segmental and whole chro-
mosome aneuploidies are relatively infrequent events (Ropars
et al. 2018). Changes in ploidy are known to provide a selec-
tive advantage under stress conditions, but can confer long-term
fitness defects when grown under nonselective conditions, as
illustrated by decreased growth and virulence (Hickman et al.
2015, 2013; Hirakawa et al. 2015). Therefore, the extent to which
these events are observed in the genomes of C. albicans isolates
must reflect the frequency of these types of genetic event and
the nature of the selective pressures that these isolates recently
faced.
Diversity has also arisen through high rates of mutation at
the nucleotide level (SNPs, insertions and deletions). Candida
albicans isolates display high levels of natural heterozygosity,
with one heterozygous SNP occurring per 200–300 bp on average
(Jones et al. 2004; Butler et al. 2009; Hirakawa et al. 2015; Ropars
et al. 2018). The levels of heterozygosity are influenced by large
LOH events, which can affect all chromosomes and are com-
mon in C. albicans isolates. LOH events are significantly elevated
under stress conditions, such as exposure to antifungal agents,
heat or oxidative stress (Forche et al. 2011; Ropars et al. 2018).
Rapid phenotypic and genetic changes have been observed in
various infection and colonisation models as well as in clinical
isolates (Forche, May and Magee 2005; Bougnoux et al. 2006, 2009;
Cheng et al. 2007; Bougnoux et al. 2008; Diogo et al. 2009; Lüttich
et al. 2013; Ene et al. 2018; Forche et al. 2018; Sitterlé et al. 2020).
This microevolution is driven primarily by de novo base substitu-
tion and short-range LOH events (Ene et al. 2018), and can clearly
impact the relationship between fungus and host (Wartenberg
et al. 2014; Tso et al. 2018; Liang and Bennett 2019) as well as resis-
tance to antifungal therapy (Coste et al. 2006; Ford et al. 2014).
THE HOST
Mammals are constantly exposed to microbes on the skin and
mucosal surfaces of the GI, respiratory and reproductive tracts.
Therefore, epithelial surfaces in the mucosal tissues repre-
sent primary sites of interaction between C. albicans and the
host (Lim et al. 2012). To prevent microbial overgrowth on the
epithelial barriers and microbial invasion of tissues, the host
actively surveys and protects its barrier surfaces via two dis-
tinct, complementary and cooperating branches of the immune
system: innate and adaptive immunity (Fig. 5). As well as form-
ing a physical barrier, epithelial cells contribute to the host
response through active recognition of microbes and evalua-
tion of their pathogenic potential. This is complemented by
myeloid cells of the innate immune system, which exploit
evolutionarily conserved pattern recognition receptors (PRRs)
to recognise microbial pathogen-associated molecular patterns
(PAMPs). Recognition of PAMPs by PRRs triggers phagocytosis
of the microbial target and/or antimicrobial effector responses
with the purpose to eradicate the pathogen. In addition, the
innate immune system, and dendritic cells (DCs) in particular,
activate the adaptive immune system. T helper (Th) cells are
activated in an antigen-specific manner to coordinate epithe-
lial defenses, improve innate immune function, activate anti-
body responses, and ultimately control the fungal load and
resolve inflammation. Through the development of immuno-
logical memory, adaptive immunity provides long-lasting pro-
tection against microbes. We address the cellular and molecu-
lar mechanisms of innate and adaptive immunity that provide
critical protection against C. albicans infection at epithelial bar-
riers where interactions between the fungus, host and micro-
biota play out. These interactions are dependent on tissue type
and are influenced by variations between individuals that affect
susceptibility to fungal infection.
Innate immunity
Fungal recognition
The innate immune system is the first line of defense against
C. albicans infection (Fig. 5). Epithelial cells (Richardson, Ho and
Naglik 2018; Nikou et al. 2019; Swidergall 2019) combine with
innate immune cells (Naglik et al. 2017; Verma, Gaffen and
Swidergall 2017; Richardson et al. 2019) to provide this defense
system, initiating anti-Candida immunity in response to fungal
recognition.
Tissue-resident phagocytes, such as macrophages and DCs,
are crucial in maintaining mucosal homeostasis (Ramirez-Ortiz
and Means 2012; Xu and Shinohara 2017; Watanabe et al. 2019).
However, innate immune cell populations differ between tis-
sues, resulting in tissue-specific variation in the induction of
innate and adaptive immune responses (see Variability in the
immune response). Following hypha formation and C. albicans
invasion, neutrophils and monocytes are rapidly recruited to the
site of infection to mediate pathogen clearance through various
antifungal responses (see Antifungal response) (Richardson et al.
2019).
Myeloid cells recognise specific microbial PAMPs using spe-
cific PRRs that fall into four main families: Toll-like receptors
(TLRs), C-type lectin receptors (CLRs), nucleotide oligomerisa-
tion domain (NOD)-like receptors (NLRs) and RigI-helicase recep-
tors (RLRs). CLRs are critical for fungal recognition (Hardison
and Brown 2012). Several types of CLR recognise C. albicans,
including Dectin-1, Dectin-2, Mincle, DC-Sign, and the man-
nose receptor (MR) (Hardison and Brown 2012; Dambuza et al.
2017; Goyal et al. 2018; Swidergall 2019). Dectin-1 recognises
fungal β-glucans, which triggers the Card9-Syk pathway, lead-
ing to Nuclear Factor-kappa B (NFκB) activation and consequent
cytokine and chemokine release (Drummond et al. 2011). In addi-
tion, dectin-1 induces phagocytosis and inflammasome activa-
tion (Kankkunen et al. 2010; Goodridge, Underhill and Touret
2012; Swidergall 2019). Dectin-2 recognises α-mannans (McGreal
et al. 2006; Saijo et al. 2010) and induces the formation of Neu-
trophil Extracellular Traps (NETs) after recognising unopsonised
C. albicans cells (Wu et al. 2019). In addition, Dectin-2 forms het-
erodimers with Dectin-3 and binds α-mannans on the surfaces
of C. albicans hyphae (Zhu et al. 2013). Mannans are also recog-
nised by Mincle, DC-Sign and the MR (Hardison and Brown 2012;
Erwig and Gow 2016; Dambuza et al. 2017).
TLR-mediated PAMP recognition activates MyD88-dependent
and TRIF signalling pathways in innate immune cells to regulate
the inflammatory response (Kawasaki and Kawai 2014; Swider-
gall 2019). TLR2 and TLR4 recognise mannoproteins, while TLR9
recognises fungal DNA (Naglik et al. 2017). In addition, together
with TLR9, the cytosolic NLR receptor NOD2 senses chitin parti-
cles (Wagener et al. 2014). NOD2-mediated recognition of chitin
was found to down-regulate inflammatory responses (Wagener
et al. 2014), which explains why NOD2 was initially described as
being redundant for the induction of inflammatory responses
against C. albicans (van der Graaf et al. 2006; van de Veerdonk
et al. 2009). Recently, the epithelial Ephrin type-A receptor 2
(EphA2) was described as a non-classical PRR that recognises β-
glucan (Swidergall et al. 2018). This receptor is expressed on neu-
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Figure 5. Immune recognition of, and immune responses against, C. albicans. Candida albicans yeast and hyphal cells are recognised by neutrophils, macrophages
and dendritic cells via pattern recognition receptors (see key). This recognition activates the expression and release of proinflammatory cytokines and chemokines
that promote the recruitment of macrophages and neutrophils to the site of infection. Epithelial cells respond to hypha formation and the subsequent secretion of
candidalysin by the fungus, by activating the expression and release of AMPs, DAMPs, chemokines and cytokines via p38/cFos and ERK/MKP1 signalling. The AMPs
attenuate fungal growth and invasion, while DAMPs and cytokines promote inflammation. Myeloid cells promote fungal killing and clearance through a combination
of phagocytosis and NETosis in the case of neutrophils. Fungal recognition leads to the maturation of dendritic cells, and their surface presentation of fungal antigens
to naı̈ve T-cells, which stimulates adaptive immunity. The interactions between antigen-presenting dendritic cells and naı̈ve T-cells induces T-cell activation and
differentiation into various effector T cell subsets that regulate mucosal immunity largely via IL-17 and IL-22 secretion, and stimulate macrophages via IFN-γ . See text.
candidiasis (OPC) (Swidergall, Solis et al. 2019). Meanwhile, the
melanoma differentiation-associated factor 5 (MDA5), a member
of the RIG-I-like receptor (RLR) family that senses viral RNA, has
been reported to also trigger an antifungal immune response,
although its ligand remains obscure (Jaeger, van der Lee et al.
2015) (Table 1).
PRRs involved in the recognition of C. albicans by myeloid
cells have been well characterised (above), but less is known
about epithelial cell PRRs that recognise C. albicans. Epithelial
cells use several types of PRR to sense C. albicans, including TLR2,
TLR4, dectin-1 and EphA2 (Weindl et al. 2007; Décanis, Savignac
and Rouabhia 2009; Cohen-Kedar et al. 2014; Swidergall et al.
2018). Despite its primordial role in the recognition of C. albi-
cans by myeloid cells, dectin-1 is thought to play a limited role
in epithelial cells (Moyes et al. 2010; Verma et al. 2017; Richard-
son, Ho and Naglik 2018). Rather, sensing of fungal β-glucans
by epithelial cells is achieved mainly by EphA2, which activates
MAPK and STAT3 signalling to induce the secretion of inflamma-
tory cytokines and antimicrobial peptides by oral epithelial cells
(Swidergall et al. 2018). PRR expression patterns vary amongst
epithelial cell types and this, together with differential myeloid
cell types, contributes to niche-specific variations in mucosal
responses against C. albicans (Nikou et al. 2019; Swidergall 2019)
(see Tissue-specific immune responses).
Epithelial cells can be activated by the C. albicans peptide
toxin, candidalysin, as well as through PRR-PAMP interactions.
This cytolytic peptide damages epithelial cells and activates the
epithelial growth factor receptor (EGFR) (Jemima Ho et al. 2019).
This, in turn, activates p38/cFos and ERK/MKP1 signalling, lead-
ing to the initiation of various effector responses (see Innate anti-
fungal responses). The epithelial response to candidalysin is par-
ticularly relevant to the transition of C. albicans from commen-
salism to pathogenicity, because candidalysin is synthesised
during hyphal growth and accumulates in the invasion pocket
as the fungus invades the epithelial surface (Moyes et al. 2016)
(see Invasion mechanisms). This response to candidalysin endows
epithelial cells with the ability to respond to the invasive hyphal
form of C. albicans, rather than its relatively benign commensal
state (Moyes et al. 2010; Naglik et al. 2017).
Innate antifungal responses
Following recognition of C. albicans by phagocytic receptors,
phagocytes such as neutrophils and macrophages can engulf
the target C. albicans cell by phagocytosis, the purpose being to
entrap and kill the pathogen (Brown 2011) (Fig. 5). Phagocyto-
sis involves rapid reorganisation of the plasma membrane and
cytoskeleton, and the imposition of mechanical force to engulf
the fungal cell and entrap it within a phagosome (Ostrowski,
Grinstein and Freeman 2016; Huse 2017). The phagosome then
undergoes a series of plasma-membrane phosphoinositide-
and Rab-dependent membrane fusion and fission events with
endolysosomal compartments that promote the assimilation
of microbicidal and lytic enzymes, and the progressive acidi-
fication of the organelle, to form the mature phagolysosome
(Brown 2011; Fairn and Grinstein 2012; Miramón, Kasper and
Hube 2013; Erwig and Gow 2016; Walpole, Grinstein and West-
man 2018). In an attempt to kill the fungus, the phagocyte
exposes its fungal cargo to a low pH, a nutrient limiting microen-
vironment and a potent mix of proteases, reactive chemical
species ROS and RNS, cation fluxes and AMPs (Lorenz, Ben-
der and Fink 2004; Brown 2011; Miramón, Kasper and Hube
2013; Erwig and Gow 2016). However, these skirmishes between
phagocyte and fungus do not always achieve fungal clearance.
This is because C. albicans has evolved molecular mechanisms
that help it to evade phagocytic recognition, escape the phago-
cyte following engulfment, and resist phagocytic killing mecha-
nisms (Austermeier et al. 2020) (see Fitness attributes and Immune
evasion).
PAMP-PRR interactions activate host cell signalling, which in
turn, induces a myriad of effector responses that are specific to
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Table 1. Pattern recognition receptors in epithelial and innate immune cells that recognise C. albicans pathogen-associated molecular patterns.
PRR family PRR Fungal PAMP Expressed in Reference
TLRs TLR2 Phospholipomannans Neutrophils, macrophages, DCs,
Epithelial cells (oral, vaginal,
intestinal)
(Kurt-Jones et al. 2002; Jouault et al. 2003; Fazeli,
Bruce and Anumba 2005; Décanis, Savignac and
Rouabhia 2009; McClure and Massari 2014)
TLR4 O-linked mannans Neutrophils, monocyte,
macrophages, DCs, epithelial cells
(oral, vaginal, intestinal)
(Netea et al. 2006; Hyung Sook Kim et al. 2016;
Fazeli, Bruce and Anumba 2005; Weindl et al.
2007; McClure and Massari 2014)
TLR9 Fungal DNA Chitin DCs, Neutrophils, macrophages,
epithelial cells (oral, vaginal,
intestinal)
(Miyazato et al. 2009; Kasperkovitz et al. 2011;
McClure and Massari 2014; Wagener et al. 2014)
CLRs Dectin-1 β-glucans Macrophages, monocytes,
neutrophils, DCs, epithelial cells
(oral, intestinal)
(Brown and Gordon 2001; Brown et al. 2002; Taylor
et al. 2002; Ariizumi, Shen, Shikano, Xu et al. 2000;
Cohen-Kedar et al. 2014)
Dectin-2 Mannoproteins
(a-mannans)




Macrophages, (Zhu et al. 2013)
DC SIGN Mannoproteins Macrophages, DCs (Cambi et al. 2003; Rappocciolo et al. 2006)
Mincle Mannoproteins Neutrophils, macrophages, DCs (Wells et al. 2008; Vijayan et al. 2012;
Martı́nez-López et al. 2019)
MR Mannoproteins Chitin DCs, macrophages (van de Veerdonk et al. 2009; Martinez-Pomares
2012; Wagener et al. 2014)
NA EphA2 β-glucans Oral epithelial cells, neutrophils (Swidergall, Solis, et al. 2019)
Galectin-3 β-mannosides Monocytes, macrophages, DCs,
neutrophils, epithelial cells
(Jouault et al. 2006)
RLRs MDA5 Unknown Monocytes, DCs, macrophages,
epithelial cells
(Plato, Hardison and Brown 2015)
NLRs NOD2 Chitin Monocytes, DCs, macrophages (Wagener et al. 2014)
Epithelial cells secrete antimicrobial peptides (AMPs) such as LL-
37, histatins and β-defensins. These AMPs exert their antifun-
gal effects by a variety of mechanisms that include binding to
the fungal cell wall or permeabilizing the fungal plasma mem-
brane (Krishnakumari, Rangaraj and Nagaraj 2009; Chang et al.
2012; Swidergall and Ernst 2014). In the oral epithelium, nitric
oxide and human-β-defensin (hBD)-2 production contribute to
the early defensive response following direct contact with C. albi-
cans and intra-epithelial invasion (Casaroto et al. 2019). In the
GI tract, mucins produced by goblet cells suppress the yeast-
hypha transition, surface adhesion and biofilm formation of C.
albicans, thereby minimizing the capacity of the fungus to attach
to, invade, and damage the epithelium (Kavanaugh et al. 2014)
(see Virulence factors).
When C. albicans does manage to colonise the epithelium,
the fungal toxin, candidalysin, plays a central role in trigger-
ing downstream responses (Kasper et al. 2018; Jemima Ho et al.
2019; Swidergall, Khalaji et al. 2019). The damage caused by can-
didalysin causes epithelial cells to passively alert professional
immune cells through their release of danger-associated molec-
ular patterns (DAMPs) or alarmins (Yang and Oppenheim 2009).
For example, S100 alarmins produced by the vaginal epithe-
lium are a potent driver of neutrophil influx during vaginitis
in a murine model of infection (Yano et al. 2010, 2014). Simi-
larly, damage to oral epithelial cells results in their release of the
alarmin IL-1ɑ, which triggers the neutrophil response to C. albi-
cans in the oral mucosa via IL-1 signalling (Dongari-Bagtzoglou,
Kashleva and Villar 2004; Altmeier et al. 2016). Epithelial cells
also produce pro-inflammatory cytokines such as IL-1β, IL-6, IL-
8, G-CSF, TNF, and IL-36 (Villar et al. 2005; Verma et al. 2018). IL-8
acts as a chemoattractant that mobilises neutrophils from the
circulation to the infection site. These neutrophils engage the
fungus directly. They also engage in cross talk with local epithe-
lial cells via TNF, thereby promoting TLR4-mediated signalling
in the epithelium to enhance protection against fungal invasion
and cell damage during oral candidiasis (Weindl et al. 2007).
Neutrophils are central players in antifungal defences due
to their rapid activation of the fungicidal oxidative burst,
(Peltroche-Llacsahuanga et al. 2000), their formation of NETs
(Kenno et al. 2016), and their release of AMPs via degranula-
tion (Urban et al. 2009) (Fig 5). Mice with C. albicans colonisa-
tion in their GI tract display enhanced neutrophil responsive-
ness and fungus-specific CD4 + T-cell responses during sys-
temic candidiasis (Shao et al. 2019). This contrasts with obser-
vations during VVC in humans and mice, where fungal suscep-
tibility is associated with uncontrolled inflammation and neu-
trophil influx (Black et al. 1998; Fidel et al. 2004). These observa-
tions reinforce the context-dependent nature of local immune
responses.
Macrophages contribute to fungal clearance through their
uptake of fungal cells, displaying a greater phagocytic capac-
ity, but lower uptake rate, than polymorphonuclear leukocytes,
(PMNs) (Rudkin et al. 2013) (Fig. 5). The hyphal form of C. albi-
cans is relatively resistant to phagocytosis (Lewis et al. 2012).
Nevertheless, macrophages still engulf portions of the hyphae,
which can become trapped in ‘frustrated phagosomes’ (Max-
son et al. 2018). After phagocytosis by macrophages, C. albicans
yeast cells can undergo morphogenesis to generate hyphae. The
yeast-hypha transition activates the NOD-and pyrin domain-
containing protein 3 (NLRP3) inflammasome. This is essential
for the release by the macrophage of pro-inflammatory IL-18 and
IL-1β, which further promote Th1/Th17 activity during infection
(Joly et al. 2009; van de Veerdonk, Joosten et al. 2011; Kasper et al.
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can help C. albicans evade macrophage killing by inducing pyrop-
tosis, rupture and death of the macrophage in vitro (Vázquez-
Torres and Balish 1997; Uwamahoro et al. 2014; Wellington et al.
2014; Kasper et al. 2018; O’Meara et al. 2018; Westman et al.
2018; Austermeier et al. 2020). Nevertheless, macrophages pro-
vide an important contribution to antifungal defences during
systemic infection. For example, the functionality of resident
renal macrophages, which is dependent on expression of the
chemokine receptor CX3CR1, is important for controlling C. albi-
cans in the early stages of a systemic infection, and for survival of
the host (Lionakis et al. 2013). Similarly, microglia play an impor-
tant role in antifungal immunity in the central nervous system,
promoting neutrophil recruitment via candidalysin induced IL-
1β and CXCL1 signalling (Drummond et al. 2019).
Mast cells modulate the antifungal potency of macrophages.
Activated mast cells enhance macrophage functionality by
improving their crawling ability and chemotaxis in response
to C. albicans stimulation (De Zuani et al. 2018). Meanwhile,
resting mast cells inhibit the phagocytosis of C. albicans by
macrophages, which suggests a role for mast cells in the main-
tenance of commensalism (De Zuani et al. 2018). Inflammatory
monocytes expressing CCR2 and Ly6C also contribute to fungal
clearance during the early stages of systemic infection. Clear-
ance is enhanced in the kidney and brain, but less so in the liver
and spleen, indicating an organ-specific role for these mono-
cytes during disseminated infection (Ngo et al. 2014).
Fungal countermeasures
During co-evolution of fungus and host, the antifungal
responses of the immune system have imposed strong selective
pressures upon C. albicans to evade these responses. Conse-
quently, the fitness of the fungus in vivo has been enhanced by
the development of a variety of fungal countermeasures that
promote immune evasion and manipulation (Underhill 2007;
Marcos et al. 2016).
A number of the fitness attributes and virulence factors,
described above, promote immune evasion (see Virulence factors
and Fitness attributes). For example, the formation of biofilms
shields C. albicans cells from immunological attack (Kernien et al.
2017). The ability of C. albicans to resist pH extremes and to
actively resist phagolysosomal acidification reduces the anti-
fungal potency of phagocytes (Vylkova et al. 2011; Bain, Gow
and Erwig 2015; Vylkova and Lorenz 2017; Westman et al. 2018).
Also, the activation of robust oxidative and nitrosative stress
responses provides a degree of protection against the toxic ROS
and RNS generated by innate immune cells (Miramón et al.
2012). These responses include secreted and cell wall bound ROS
detoxifying enzymes that help to counter immune attack (Crowe
et al. 2003; Fradin et al. 2005; Dantas et al. 2015). However, C. albi-
cans is sensitive to certain combinations of stress encountered
within the phagosome (Kaloriti et al. 2014; Kos et al. 2016).
Hypha formation reduces the exposure of C. albicans to
phagocytic killing because lengthy hyphal cells are harder to
engulf, and hyphae have been reported to display lower levels
of the inflammatory MAMP, β-1,3-glucan, at their cell surface
(Gantner, Simmons and Underhill 2005; Bain et al. 2014; Mukare-
mera et al. 2017). Furthermore, C. albicans can undergo yeast-
hypha morphogenesis following phagocytosis by macrophages,
rupturing the phagosome and eventually leading to host cell
death and fungal escape (Lewis et al. 2012; Ermert et al. 2013;
Vylkova and Lorenz 2017). Indeed, the fungus is capable of trig-
gering pyroptosis, inflammasome activation and cell death in
a macrophage that has engulfed it (Uwamahoro et al. 2014;
Wellington et al. 2014; O’Meara et al. 2015; Kasper et al. 2018), and
can also induce host cell death through metabolic competition
for glucose (Tucey et al. 2018; Tucey et al. 2020). Like other fungal
pathogens, C. albicans may also escape the macrophage with-
out lysing the host cell (Bain et al. 2012), although this mode of
escape is thought to be rare.
Members of the secreted aspartic protease family (Sap1-3)
promote immune evasion by degrading complement proteins
(C3b, C4b, C5) thereby reducing the inhibitory potential of the
complement system (Gropp et al. 2009). Candida albicans also
expresses complement binding proteins at its cell surface that
reduce the efficacy of the complement system (Poltermann et al.
2007; Zipfel and Skerka 2009). Pra1, which promotes zinc assim-
ilation in C. albicans (see Fitness attributes), also interacts with
complement regulators and plasminogen. In addition, Pra1 was
the first protein described to bind to C4BP, which regulates the
classical and lectin complement pathways and avoids C3b and
C4b deposition on the fungal surface when captured by C. albi-
cans, impeding complement cascade progression (Luo et al. 2009,
2011; Zipfel, Hallström and Riesbeck 2013). Furthermore, C. albi-
cans secretes prostaglandins that modulate host immunity by
downregulating chemokine and TNF production (Noverr et al.
2001). On the other hand, host immune mediators such as IFNγ ,
IL-17, TNF and PGE2 influence C. albicans growth, filamentation
and biofilm formation (Kalo-Klein and Witkin 1990; Noverr and
Huffnagle 2004; Zelante et al. 2012; Rocha et al. 2017).
More recently, it was found that C. albicans yeast cells can
evade phagocytic recognition by actively masking β-1,3-glucan
at their cell surface. Interestingly the fungus exploits host sig-
nals, such as lactate, hypoxia, iron limitation and ambient pH,
to modulate its β-1,3-glucan exposure (Ballou et al. 2016; Sher-
rington et al. 2017; Lopes et al. 2018; Pradhan et al. 2018; Cot-
tier et al. 2019; Pradhan et al. 2019). Reducing the levels of β-
1,3-glucan exposure leads to the attenuation of anti-Candida
immune responses (Ballou et al. 2016; Sherrington et al. 2017;
Lopes et al. 2018; Pradhan et al. 2018, 2019) and promotes dis-
ease progression (Lopes et al. 2018). Indeed, the fungus appears
to use these host signals to anticipate impending immune attack
and to protect itself by activating immune evasion mechanisms
(Alistair J P Brown et al. 2019). These, and other anticipatory
responses (Rodaki et al. 2009; Brunke and Hube 2014), provide
strong evidence for the co-evolution of C. albicans with its host
(Brown, Larcombe and Pradhan 2020).
Adaptive immunity
The adaptive immune system evolved to establish long-term
protection through its ability to generate immunological mem-
ory (Fig. 5). The key role played by this arm of the immune
system in providing surveillance of commensal organisms is
reflected in the fungal dysbiosis that occurs in the absence of
adaptive immunity (Lanternier, Cypowyj et al. 2013). The adap-
tive immune system involves B and T cells. B cells are essential
for the production of antibodies, whereas T helper (Th) cells pro-
vide essential support for mucosal host defense and the innate
immune response.
Candida albicans-specific antibodies are detectable in individ-
uals that have been exposed to the fungus (Swoboda et al. 1993;
López-Ribot et al. 2004; Pitarch et al. 2006). Their role in the con-
trol of fungal colonisation remains unclear, although the pres-
ence of anti-C. albicans antibodies might provide protection to
mice against a potentially lethal systemic challenge (Matthews
et al. 1991), as does gut colonisation through the development of
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some time, it has been thought that antibodies may have diag-
nostic as well as therapeutic value (Matthews et al. 1988). Recent
studies have reinforced their diagnostic potential (Wang et al.
2020), and recombinant anti-C. albicans antibodies have been
shown to display therapeutic potential in preclinical models of
infection by improving phagocytosis (Rudkin et al. 2018).
T cells exist as various subtypes that contribute differen-
tially to antifungal immunity (Borghi et al. 2014; Verma et al.
2014; Lionakis and Levitz 2018) (Fig. 5). Among CD4+ T cells,
Th1 and Th17 cells promote the phagocytic clearance of fun-
gal cells through the release of inflammatory cytokines such
as IFN-γ and IL-17A/F, respectively, and these T cell subsets
are critical for protective antifungal immunity. On the other
hand, Th2 cells counter-regulate Th1 and Th17 responses, which
can favour fungal persistence and promote allergic manifesta-
tions. Regulatory T cells (Tregs) maintain the homeostatic bal-
ance between these responses and limit inflammation as the
infection is cleared. Th17 cells represent a major subset, and Th1
and Th2 cells minor subsets, of the human C. albicans-specific T
helper cell population (Becattini et al. 2015; Bacher et al. 2019).
However, additional T helper cell subsets have been described
more recently (Eyerich et al. 2011; Becker et al. 2016). More-
over, T helper cells express plasticity. For example, C. albicans-
specific Th17 cells can adopt the ability to produce additional
cytokines, such as the Th1 prototypic cytokine IFN-γ (Zielinski
et al. 2012). Cytotoxic (CD8+) T-cells may also play a role in anti-
Candida immunity (Beno, Stöver and Mathews 1995; Marquis
et al. 2006).
The major protective role of Th17 cells in antifungal immu-
nity is illustrated by the strong association of human defects
in this T cell compartment and IL-17 signalling with uncon-
trolled fungal growth on mucosal surfaces and the skin (Puel
et al. 2011; Ling et al. 2015; Li et al. 2017; Puel 2020). Consistently,
mice with defects in the IL-17 signalling pathway display a
reduced ability to cope with C. albicans administered via oropha-
ryngeal or epicutaneous routes (Conti et al. 2009; Gladiator et al.
2013; Kashem, Igyarto et al. 2015), while IFN-γ -producing Th1
cells may have a disease-promoting effect (Igyártó et al. 2011).
Also, the expansion of fungus-specific Th1 and Th17 cells in
response to mucosal colonisation enhances protection against
subsequent systemic C. albicans infections in mice (Romani
et al. 1994; Shao et al. 2019). However, T cell- and IL-17-defects
do not alter susceptibility to systemic infection in humans
(Lionakis 2014).
CD4 + T cells are characterised by their ability to respond
in an antigen-specific manner. Antigen-specific activation
of (naı̈ve) T cells depends on their interactions with DCs
that present antigen on MHC-II molecules, and provide co-
stimulatory and polarising cytokine signals. DCs are divisible
into several subsets, most of which reside in peripheral tis-
sues in close proximity to the microbiota where they inter-
act with C. albicans. In response to PRR-mediated activation,
DCs undergo a maturation program and migrate to the drain-
ing lymph nodes, where they encounter, activate, and prime
antigen-specific T cells. This process relies on a tightly coordi-
nated interplay between the innate and adaptive immune sys-
tem (Fig. 5). The priming of T cells comprises of three steps.
First, the recognition of peptide-MHC-II complexes by T cells
via their T cell receptor (TCR) defines the antigen-specificity of
the response. Second, this interaction is supported by adhesion
and co-stimulatory molecules, which are induced at the cell sur-
face of DCs in response to microbial stimulation, and these form
an immune synapse that stimulates T cell proliferation. Third,
the cytokine microenvironment directs the T cell differentiation
towards distinct Th lineages via STAT (signal transducer and
activator of transcription) signalling and the induction of fate-
determining transcription factors (Wüthrich, Deepe and Klein
2012).
While antigens and the polarisation-inducing microbial sig-
nals are functionally distinct, the physical connection between
antigen and PAMP enhances the efficiency of the T cell acti-
vation and differentiation process. Some of the few nat-
urally processed and presented C. albicans antigens identi-
fied so far are glycosylated cell wall proteins, such as Mp65
(Pietrella et al. 2008) and Als3 (Bär et al. 2012). These manno-
proteins can therefore serve concomitantly as a source of
MHC-II antigen cargo as well as PAMPs. Such antigens sup-
port the coordinated process of antigen presentation and T cell
polarisation.
The process of DC maturation is shaped by the specific PRR
pathways that become activated in DCs following a microbial
encounter (Fig. 5). This then determines the profile of cytokines
that are produced, and hence directs the fate of the Th cell polar-
isation. Fungal cell wall components such as mannans and β-
1,3-glucans trigger Syk- and CARD9-dependent cytokine signa-
tures characterised by IL-23, IL-6, and IL-1β, which collectively
instruct Th17 differentiation (LeibundGut-Landmann et al. 2007;
Robinson et al. 2009; Saijo et al. 2010). IL-6 and IL-1β, together
with TGF-β in mice, drive the commitment of Th17 cells, while
IL-23 promotes lineage maintenance in a STAT3- and RORγ t-
dependent manner (Korn et al. 2009). Th17 cell differentiation
is further modulated by the antigen dose and by tissue-specific
cues.
Th17 cells produce the IL-17 family of effector cytokines:
IL-17A and IL-17F as well as IL-22. These cytokines act pri-
marily on epithelial cells and control the expression of genes
linked to antimicrobial defense and tissue repair (Conti et
al. 2009, 2016). IL-17 can also play an important role in pro-
moting neutrophil recruitment (Liang et al. 2007), although,
in the oral mucosa, the neutrophil response against C. albi-
cans is largely independent of IL-17 (K Trautwein-Weidner et al.
2015). Instead, it depends on IL-1 and chemokines produced by
epithelial cells in response to virulent C. albicans strains (Alt-
meier et al. 2016). While the functions of IL-17A and IL-17F are
related, they do play non-redundant roles in host defense (Glad-
iator et al. 2013; Whibley et al. 2016). Similar to IL-17A and IL-
17F, IL-22 also induces AMPs and contributes to fungal control
(Liang et al. 2006). However, in contrast to IL-17A and IL-17F,
defects in the IL-22 pathway have a minor impact on fungal
control in experimentally infected mice (Conti et al. 2009; De
Luca et al. 2013). Lately, IL-22 and IL-17A/F have been found to
function nonredundantly during OPC, and IL-22 was shown to
regulate the responsiveness of the epithelium to IL-17 (Aggor
et al. 2020).
CD4 + T cells are the major source of IL-17 during responses
to C. albicans at barrier tissues, but other sources may also con-
tribute. CD8+ αβ T cells can produce IL-17 in response to C.
albicans (and other fungi), and these cells may play a compen-
satory role in the absence of CD4 + T cells (Nanjappa et al. 2012;
Hernández-Santos et al. 2013). Moreover, innate lymphocytes
and innate lymphoid cells (ILCs) can generate IL-17 (Cua and
Tato 2010; Gladiator et al. 2013). In experimental models of oral
infection, where naı̈ve mice were exposed to a virulent C. albi-
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tion of IL-17 in ILCs, γ δ T cells and a tissue-resident population
of αβ T cells that respond in a TCR-independent manner (Spar-
ber et al. 2018; Conti, Peterson et al. 2014; Kashem, Riedl et al.
2015; Verma et al. 2017). These three cellular subsets act in a
partially redundant manner (Conti, Peterson et al. 2014; Glad-
iator et al. 2013). Therefore, although small in size, the IL-17-
producing ILC population can compensate for the absence of
αβ and γ δ T cells during acute OPC (Gladiator et al. 2013). The
extent to which innate sources of IL-17 contribute to antifungal
defense in humans to maintain host-fungus homeostasis is not
yet clear.
As a result of their exposure to C. albicans in the microbiota,
most humans produce C. albicans-specific memory Th17 cells.
In the circulation, these cells display the phenotype of effector
memory T cells, which can respond rapidly to fungal exposure
(Acosta-Rodriguez et al. 2007). In the skin, their expression of
CD69 and CD103 characterises these C. albicans-specific memory
Th17 cells as tissue-resident memory cells (Park et al. 2018). The
maintenance of C. albicans-specific T cells is dependent on the
persistence of the fungus in the host (Park et al. 2018; Shao et al.
2019; Kirchner and LeibundGut-Landmann 2020). The relevance
of tissue-resident memory T cells for local immunosurveillance
of C. albicans in barrier tissues was confirmed recently in a model
of stable C. albicans commensalism, where tissue-resident mem-
ory T cells were sufficient to prevent fungal overgrowth (Kirch-
ner and LeibundGut-Landmann 2020). The relationship between
circulating and tissue-resident memory T cells directed against
C. albicans remains to be determined, although their shared T
cell receptor sequences suggest a common origin for both pop-
ulations of memory Th17 cells (Park et al. 2018). Clearly, IL-
17 immunity plays an important protective role in antifungal
immunity. However, IL-17 signalling also has pathogenic poten-
tial, such as in the context of some autoimmune disorders (Eye-
rich, Dimartino and Cavani 2017) (see Immunopathology in candidi-
asis).
FoxP3 + IL-2Rα(CD25+) regulatory T cells (Tregs) are key
mediators of immune regulation that provide endogenous
regulatory mechanisms that can prevent potentially harm-
ful immune responses. These Tregs confer immune tolerance
through the expression of IL-10 and TGF-β, the consumption
of IL-2, and the expression of inhibitory receptors that tar-
get T cells directly or indirectly via modulation of DC func-
tionality (Romano et al. 2019). Furthermore, Tregs are develop-
mentally linked to Th17 as they can promote Th17 differenti-
ation by consumption of IL-2 (a cytokine that constrains Th17
differentiation) and, in mice, by providing TGF-β (which pro-
motes Th17 polarisation) (Pandiyan et al. 2011). While Tregs
directed against C. albicans are largely expanded in the physi-
ological T cell repertoire in humans (Bacher et al. 2014), their
contribution to the maintenance of stable C. albicans home-
ostasis in barrier tissues remains unclear. In a murine model
of C. albicans commensalism, Tregs were dispensable for sta-
ble fungal colonisation and an absence of Tregs did not result
in dysregulation of the antifungal Th17 response (Kirchner
et al. 2019). Instead, the kynurenine pathway, which regu-
lates tryptophan catabolism, might contribute to antifungal tol-
erance and limit inflammation in mucosal tissues (De Luca
et al. 2013).
To summarise, a combination of epidemiological data, asso-
ciation studies in human primary immunodeficiency (PID) syn-
dromes, in vitro challenges with primary human cells, and exper-
iments in various mouse models of superficial candidiasis, have
highlighted the importance of Th17 immunity during long-term
colonisation of barrier tissues by C. albicans, and the fine lines
between fungal commensalism and pathogenicity, and health
and disease.
Tissue-specific variability of the mucosal immune
response
Candida albicans colonises and causes infections in a range
of different tissues, each of which characterised by a differ-
ent architecture, nutrient supply, metabolic environment, and
immune cell composition. Consequently, distinct host defense
mechanisms against C. albicans exist in each tissue. Adaptive
T cell immunity predominates in fungal control at the skin
and most mucosal barriers (except for the vaginal mucosa),
whereas innate myeloid cell-mediated mechanisms dominate
the immune response to systemic infection (Lionakis 2014). Neu-
trophils and inflammatory monocytes have also been linked to
antifungal immunity in barrier tissues. This notion has arisen
primarily from experiments involving acute infections of pre-
viously C. albicans-naı̈ve mice with highly virulent C. albicans
strains, which trigger a strong inflammatory response and tissue
damage. Under such conditions, inflammatory leukocytes (pri-
marily neutrophils) are rapidly recruited to the infected tissues
(Conti et al. 2009; K Trautwein-Weidner et al. 2015; Bai et al. 2020)
where they prevent deep tissue invasion and mediate the rapid
elimination of C. albicans (K Trautwein-Weidner et al. 2015). In
contrast, C. albicans colonisation of barrier tissues is not gener-
ally accompanied by tissue inflammation (Schönherr et al. 2017),
just as fungal commensalism in healthy individuals is not asso-
ciated with inflammation.
In the vaginal mucosa, pathogenesis is thought to
arise largely as a consequence of neutrophil-mediated
immunopathology rather than a defect in T cell immunity
(Fidel et al. 2004; Giraldo et al. 2012; Rosati, Bruno, Jaeger, Kull-
berg et al. 2020). Symptomatic infection correlates with elevated
infiltration of neutrophils that are not able to limit the fungal
burden (Yano, Noverr and Fidel 2017; Ardizzoni et al. 2020).
In contrast to the vaginal mucosa, where Th17 cells do not
provide a major protective contribution, Th17 immunity is cru-
cial for controlling the commensal colonisation of C. albicans on
the skin and the mucosa of the oral cavity and GI tract (Spar-
ber and LeibundGut-Landmann 2019). Experiments in mice have
shown that the mechanisms of Th17 induction vary depend-
ing on the tissue. This is probably due to differences in the
composition of antigen-presenting cells between the different
tissues. Langerhans cells (LCs) are the predominant DC sub-
set in the skin epidermis, but this cell type only represents a
fraction of the DC population in the oral and vaginal epithe-
lium (Hovav 2018). In the skin, LCs prime C. albicans-specific
Th17 cells (Kashem, Igyarto et al. 2015), but they appear dispens-
able in the oral mucosa where conventional migratory DCs and
monocyte-derived inflammatory DCs execute this task (Kerstin
Trautwein-Weidner et al. 2015). In the gut, CX3CR1 + mononu-
clear phagocytes are essential for the initiation of adaptive
immunity against C. albicans (Leonardi et al. 2018). Meanwhile,
in the vaginal mucosa, plasmacytoid DCs may dominate and
instruct a primarily tolerogenic response (LeBlanc, Barousse and
Fidel 2006). Therefore, DCs are central coordinators of antifun-
gal immunity. This relates not only to T cell activation in barrier
tissues, but also to systemic candidiasis where DCs are indis-
pensable for organising neutrophil-mediated innate immunity
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Explanatory Box 1: Immunopathology
Neutrophils are amongst the first immune cells to be
recruited from the bloodstream to the site of infection
or tissue injury. Their recruitment is a multi-step pro-
cess initiated by changes in the endothelium, and is
induced by inflammatory mediators secreted by epithelial
and tissue-resident immune cells (Kolaczkowska and Kubes
2013). At the site of infection, neutrophils clear pathogens
through a combination of mechanisms including phago-
cytosis, degranulation, and NET formation (Selders et al.
2017; Rosales 2018). However, the secretion of ROS, pro-
teolytic enzymes and AMPs by neutrophils can also lead
to tissue injury and collateral damage (Wang 2018). Neu-
trophils die during the process of NETosis and release their
nuclear and cytoplasmic contents. This can result in the
presentation of auto-antigens and the production of pro-
inflammatory cytokines, DAMPs and alarmins (Wang 2018;
Wilgus 2018). DAMPs induce further neutrophil recruitment
(Pittman and Kubes 2013), promoting a hyperinflammatory
loop that, if not dampened by anti-inflammatory mech-
anisms, can exaggerate inflammation and tissue damage
(Tisoncik et al. 2012). The adaptive immune system also
mediates immunopathology via T cells, and Th17 cells in
particular. C. albicans-specific Th17 cells promote inflam-
mation and mediate immunopathological effects (Bacher
et al. 2019; Shao et al. 2019; Hurabielle et al. 2020). Key
anti-inflammatory mechanisms are mediated by Treg cells,
myeloid suppressor cells, and anti-inflammatory molecules
such as IL-1-family cytokines (IL-1Ra, IL-37, IL-38, IL-
36Ra), IL-10, α1-antitrypsin, soluble cytokine receptors, and
cytokine binding proteins (Netea et al. 2017; Dinarello 2018).
The resolution of inflammation is an active process com-
prising of numerous signalling pathways that inhibit the
inflammatory loop and limit tissue injury, as well as pro-
moting pathogen clearance (Netea et al. 2017).
Immunopathology in candidiasis
The innate and adaptive immune responses provide essential
protection against mucosal and life-threatening systemic infec-
tions, but uncontrolled inflammation can contribute to disease
by causing immunopathology (Explanatory Box 1). There is a bal-
ance between immune protection and immunopathology. Using
mouse models of systemic candidiasis, some investigators
found that type I interferons promote fatal immunopathol-
ogy through the recruitment and activation of inflammatory
monocytes and neutrophils (Majer et al. 2012), whereas others
observed reduced survival and concluded that type I interferons
are crucial for immunity against C. albicans (del Fresno et al.
2013). Neutrophil accumulation in the kidneys and lung has
been shown to cause immunopathology and organ failure in
murine models (Lionakis et al. 2011; Desai and Lionakis 2018;
Lee et al. 2018). During VVC in mice and humans, candidalysin-
induced mucosal damage allows DAMPs and proinflammatory
cytokine secretion, which promotes neutrophil recruitment and
the exacerbation of inflammation (Richardson et al. 2018). More-
over, activation of the NLRP3 inflammasome and unrestrained
IL-1β production can induce a hyperinflammatory state at the
vaginal mucosa and acute symptoms of VVC (Rosati, Bruno,
Jaeger, Ten Oever et al. 2020). This is influenced by endogenous
anti-inflammatory mediators and environmental conditions
(Rosati, Bruno, Jaeger, Ten Oever et al. 2020) such as short-chain
fatty acids (SCFAs) derived from resident bacteria, which also
play a crucial role in the immunopathology of oral candidiasis in
mice (Bhaskaran et al. 2018). Th17 polarisation associated with
intestinal C. albicans colonisation can be deemed as protective
as it can cross-protect against systemic disease (Shao et al.
2019). However, these specific Th17 cells also contribute to
allergic airway inflammation (Bacher et al. 2019; Shao et al.
2019) through cross-reactivity to the lung pathogen Aspergillus
fumigatus (Bacher et al. 2019). C. albicans-specific Th17 cells can
also promote inflammation in the skin and thereby contribute
to psoriaform pathology (Hurabielle et al. 2020).
Several endogenous mechanisms regulate inflammation
to maintain the balance between immune protection and
immunopathology (Netea et al. 2017). The neutrophil response
protects against C. albicans by inducing neutrophil chemokines
(Mengesha and Conti 2017; Sparber and LeibundGut-Landmann
2019), but these also promote inflammation. The IL-1 fam-
ily of cytokines, which drive neutrophil responses (Altmeier
et al. 2016; Verma et al. 2018), are regulated by endoge-
nous anti-inflammatory cytokines. For example, IL-37 compro-
mises protection against systemic infection by reducing neu-
trophil influx (van de Veerdonk et al. 2014), but the capac-
ity to reduce this influx potentially makes IL-37 a key player
for preventing immunopathology. Other endogenous regulators
include IL-1Ra, which neutralises IL-1 signalling and dampens
NLRP3 Inflammasome activity, thereby contributing to reduced
immunopathology (Borghi et al. 2015). The anti-inflammatory
cytokines IL-36Ra and IL-38 can also attenuate the C. albicans-
induced Th17 response (van de Veerdonk et al. 2012).
Clearly, molecules that target the IL-17 and IL-1 signalling
pathways may have potential therapeutic value as treatments
for immunopathology associated with candidiasis. Targeting
the NLRP3 inflammasome has also been suggested as a poten-
tial strategy to ameliorate inflammation during VVC (Bruno
et al. 2015; Richardson et al. 2018). However, the fine bal-
ance between protection and pathology must be deciphered
before the accurate therapeutic modulation of these path-
ways can be achieved. Furthermore, the role and therapeu-
tic applications of immunomodulators such as Indoleamine-
pyrrole 2,3-dioxygenase 1 (IDO1), an enzyme producing tolero-
genic kynurenines (De Luca et al. 2013), should be further evalu-
ated.
Trained Immunity
The classical paradigm of host immune defense is based on the
ability of the innate immune system to provide short term pro-
tection, combined with the capacity of adaptive immunity to
mount immunological memory and provide long-lasting protec-
tion against the same pathogen. A growing body of evidence
now shows that the innate immune system is able to gener-
ate immunological memory, independently of adaptive immu-
nity. This phenomenon, which is termed ‘trained immunity’, has
been described in invertebrates, plants, and mammals (Kurtz
and Franz 2003; Durrant and Dong 2004; Netea, Quintin and van
der Meer 2011), and is based on functional reprogramming of
innate immune cells.
Candida albicans, and individual components of its cell wall,
are potent immune modulators (see Cell wall). Even in mice
that are deficient in T and B lymphocytes (i.e. lack adaptive
immunity), an initial non-lethal exposure to C. albicans provides







sre/article/45/3/fuaa060/6000215 by guest on 25 Septem
ber 2021
18 FEMS Microbiology Reviews, 2021, Vol. 45, No. 3
et al. 1986). This resistance to re-infection was described as a
macrophage-dependent mechanism associated with enhanced
production of the proinflammatory cytokines TNF, IFN-γ , and
IL-1β (Vecchiarelli et al. 1989). Moreover, protection was not
restricted to disseminated candidiasis: cross-protection to unre-
lated pathogens such as Staphylococcus aureus was also induced
(Bistoni et al. 1986; Netea, Quintin and van der Meer 2011).
Further studies demonstrated that stimulation with C. albi-
cans or β-glucan, leading to activation of the dectin-1/PI3K-
Akt-mTOR axis (Quintin et al. 2012; Cheng et al. 2014), elicits
epigenetic remodeling of the transcriptional repertoire (Saeed
et al. 2014). This leads to a shift in immune cell metabolism
from oxidative phosphorylation to aerobic glycolysis (the War-
burg effect) (Cheng et al. 2014), and enhanced pro-inflammatory
cytokine production (Quintin 2019; Netea et al. 2020). Further
studies revealed that β-glucan-primed monocytes differentiate
into macrophages that display highly active metabolic activ-
ity and increased glucose consumption (Leonhardt et al. 2018).
Interestingly, C. albicans-induced trained immunity is defective
in chronic mucocutaneous candidiasis (CMC) patients, indicat-
ing that STAT-1 signalling is involved in the induction of trained
immunity (Ifrim et al. 2015).
The induction of trained immunity depends strongly on
the nature of the ligand and the PRR that is activated. For
example, while TLR4 activation by lipopolysaccharide (LPS) can
lead to a state of immunotolerance or immunoparalysis that
compromises antifungal host defense (Grondman et al. 2019),
the TLR4 agonist, monophosphoryl lipid A (MPLA), has been
recently reported as an inducer of trained immunity (Fenster-
heim et al. 2018). Immunotolerance in sepsis patients increases
the risk of secondary infections, including candidiasis (Otto et al.
2011). Conversely, trained immunity induced by C. albicans can
enhance protection against sepsis in mice (Cheng et al. 2014).
In addition, C. albicans colonisation of the GI tract provides pro-
tection against a variety of systemic pathogens (Tso et al. 2018).
Therefore, the temporary transcriptional and metabolic rewiring
via β-glucan-administration might provide a strategy to revert
the LPS-induced tolerance of innate immune cells. Indeed, phar-
macological targeting in myeloid cells, for example, by inhibi-
tion of the phosphatase SHIP-1 (Saz-Leal et al. 2018) or the IRG1-
itaconate-SDH axis (Domı́nguez-Andrés et al. 2019), could play a
pivotal role in harnessing beneficial effects of trained immunity
(Mulder et al. 2019).
Variability amongst individuals
Variation between individuals influences the host-fungus inter-
action and susceptibility to fungal infection. The identification
of candidate genetic traits is, therefore, pivotal for the selec-
tion of patients that would benefit from host-directed therapy
or antifungal prophylaxis.
The effectiveness of a person’s anti-fungal immune response
is severely impaired if they acquire an immunocompromised
status, for example through HIV-induced AIDS, neutropenia
induced by cytostatic therapy, or immunosuppressive therapy
during organ transplantation. Furthermore, certain genetic vari-
ations compromise the efficacy of immune pathways and exert
strong detrimental effects upon antifungal immunity. Genetic
susceptibility to fungal infection has been comprehensively
studied and reviewed (Lionakis 2012). Mutations in STAT1, for
instance, predispose individuals to CMC (Puel et al. 2011; van
de Veerdonk, Plantinga et al. 2011). Also, inborn errors in Th17
or CARD9 immunity are associated with recurrent mucosal
and invasive candidiasis, respectively (Puel 2020). Interestingly,
genetic immunodeficiencies often lead to different susceptibili-
ties to fungal infections of the mucosal surfaces, skin, and nails.
Similarly, HIV patients develop oropharyngeal candidiasis (OPC)
more often than vaginal infections (VVC) (Fidel 2002). This is
consistent with the existence of distinct anti-Candida immune
mechanisms in different mucosal niches (see Tissue-specific vari-
ability of the immune response).
Many genetic polymorphisms in PRRs have been associated
with impaired antifungal host defense (Jaeger, Stappers et al.
2015). For instance, SNPs in the TLR1 and TLR4 genes increase the
risk of candidaemia (Plantinga, Johnson et al. 2012; Van der Graaf
et al. 2006), and a variable number tandem repeat (VNTR) poly-
morphism in the NLRP3 gene is associated with increased sus-
ceptibility to VVC (Jaeger et al. 2016). Susceptibility to mucosal
or systemic candidiasis varies depending on the nature of the
receptor or effector molecule that is mutated. For example, a
homozygous mutation in the dectin-1 gene is more likely to pre-
dispose the individual to CMC (Ferwerda et al. 2009), whereas
defects in CARD9 result in systemic, mucosal, and subcutaneous
candidiasis (Drewniak et al. 2013; Lionakis and Holland 2013;
Lanternier, Pathan et al. 2013). Interestingly, CARD9-deficient
individuals are prone to fungal proliferation in the central ner-
vous system (CNS), but not in the kidney, spleen, or liver (Drum-
mond et al. 2015), which highlights an organ-specific CARD9-
dependent immune mechanism, such as IL-1β/CXCL1-mediated
neutrophil recruitment by microglial cells (Drummond et al.
2019).
Genome-wide association studies (GWAS) have been per-
formed to identify genetic polymorphisms associated with sus-
ceptibility to infectious diseases (Newport and Finan 2011), and
overviews of comprehensive multi-omic systems approaches
towards an understanding of host-fungal interactions have been
published (Horn et al. 2012; Culibrk, Croft and Tebbutt 2016). The
first GWAS analysis for fungal infections identified three novel
risk loci associated with increased susceptibility and severity
of candidaemia: CD58, LCE4A-C1orf68, and TAGAP (Kumar et al.
2014). Although GWAS is an ideal approach for the identifica-
tion of novel genetic associations with susceptibility to fungal
infections, it is difficult to achieve a high level of statistical sig-
nificance (<5 × 10–8) with the generally small cohorts of can-
didaemia patients available (Manolio 2010; Chapman and Hill
2012). Hence, the power of GWAS can be enhanced by combin-
ing the outputs with systems biology, transcriptomics and avail-
able knowledge of immunology and microbiology, to pinpoint
disease-associated genetic determinants. The functional valida-
tion of putative hits in an independent cohort can underline the
relevance of newly identified genetic associations. For instance,
the integration of gene expression data and functional genomics
revealed the importance of type I IFNs in the host response
against C. albicans (Smeekens et al. 2013; Jaeger, van der Lee et al.
2015). Also, using a computational approach based on publicly
available transcript profiling data sets, MALT1, SERPINE1, ICAM1,
IL8, and IL1A were discovered as common immune response-
inducing genes during fungal infection (Kidane, Lawrence and
Murali 2013). Furthermore, combining genetic data from candi-
daemia cohorts with immune-profiling of C. albicans-stimulated
cells, the MAP3K8 and SERPINA1 genes were shown to contribute
to candidaemia susceptibility (Matzaraki et al. 2017). Mapping
genetic determinants to variability in transcription or cytokine
levels can lead to the identification of expression quantitative
trait loci (eQTL) or cytokine-quantitative trait loci (cQTL), respec-
tively (i.e. the genetic variation associated with different levels of
transcriptional and cytokine responses). The analysis of eQTLs
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affects the anti-Candida host response and of the populations of
cells involved in the clearance of the pathogen (de Vries et al.
2020). The investigation of cQTL datasets revealed SIGLEC15 as
a susceptibility factor for RVVC (M Jaeger et al. 2019) as well as
susceptibility pathways, such as lipid homeostasis and inflam-
mation, that affect the response of monocytes to fungal blood-
stream infections (Martin Jaeger et al. 2019).
In addition to genetic variability, external factors such as
broad-spectrum antibiotics or immunosuppression regimens
negatively influence the microbial community. This, in turn,
affects metabolic homeostasis (Zarrinpar et al. 2018) and host
resistance to both antibiotic-resistant microbes and fungal
pathogens (Ubeda and Pamer 2012). For instance, preexposure to
antibiotics not only increases Candida colonisation levels in the
GI tract, but also facilitates disruption of the mucosal barrier and
leads to C. albicans bloodstream infections (Das et al. 2011; Gutier-
rez et al. 2020). This could be due to the loss of protection from
microbiota-derived metabolites, such as short-chain fatty acids
(Guinan et al. 2019; Gutierrez et al. 2020). Moreover, antibiotic-
induced dysbiosis can reduce pro-inflammatory cytokine pro-
duction towards LPS stimulation (Lankelma et al. 2016). Thus,
supplementation with probiotics may represent a useful strat-
egy to counterbalance the negative effects of antibiotic-induced
therapy and improve the host immune response against fungal
infections (Ubeda and Pamer 2012).
THE MICROBIOTA
Gastrointestinal (GI) tract
The collection of microbes that colonises the GI tract is termed
the ‘gut microbiota’, and is composed of bacteria, archaea,
eukaryotic microbes and viruses. Thousands of microbial strains
have been detected in the human gut, and these microbes
can be important contributors to human health and disease
(Fig. 6). For example, the gut microbiota plays key roles in nutri-
tion (by degrading dietary components that would otherwise
pass through the GI tract undigested), in host immune devel-
opment and maintenance, and in protecting the host against
pathogenic microbes, including C. albicans. This latter process,
termed ‘colonisation resistance’, is multifactorial. It involves both
microbe-microbe interactions (such as competition for nutri-
ents, niches and binding sites, and the release of antimicrobial
substances), and host-microbe interactions (whereby the micro-
biota can stimulate the host’s immune system or strengthen the
gut epithelial barrier against invading pathogens) (Lawley and
Walker 2013). Significantly, an individual’s degree of colonisa-
tion resistance is thought to be strongly influenced by the com-
position of their gut microbiota, with some individuals being
more intrinsically resistant to infection than others (Ubeda
et al. 2010).
Most gut microbiota studies have focussed on the bacte-
rial component, which accounts for the greatest proportion of
biomass present by far (Qin et al. 2010; Arumugam et al. 2011).
These gut bacteria display both antagonistic and mutualistic
relationships with C. albicans and other members of the fun-
gal community (mycobiota) that help to maintain homeosta-
sis in the human GI tract. Fungi represent just ∼0.1% of the GI
tract biosphere, which makes the fungal mycobiota more chal-
lenging to study than the bacterial microbiota (Underhill and
Iliev 2014). Also, mechanical lysis steps are best employed dur-
ing DNA extraction to recover reasonable quantities of fungal
DNA (Angebault et al. 2018), and because different extraction and
sequencing methods have been used, gut mycobiota composi-
tional analyses are difficult to compare between studies (Belle-
main et al. 2010; Tedersoo et al. 2015; Tedersoo and Lindahl 2016;
Huseyin et al. 2017; Angebault et al. 2018). Many mycobiota stud-
ies provide information about genera (e.g. Candida) rather than
species (e.g. C. albicans). This section discusses causes of vari-
ability in the bacterial microbiota of the human GI tract and,
where possible, the impact upon the GI mycobiota (fungal micro-
biota), and C. albicans in particular.
Variability along the GI tract
The compartments of the human GI tract, including the small
intestine, caecum and large intestine (colon), have variable
physiology and, as a result, each harbours distinct microbial
communities (Fig. 6). Compared to the colon, the small intes-
tine contains comparatively high levels of stomach acids, oxy-
gen and antimicrobials, and is characterised by a short transit
time. The small intestine also contains higher concentrations
of bile acids, which are bactericidal to certain microbial species
(Donaldson, Lee and Mazmanian 2016). Accordingly, the micro-
bial community of the small intestine is less diverse than the
colonic microbiota, and tends to be dominated by fast-growing
facultative anaerobes such as streptococci and Proteobacteria
that have the ability to adhere to epithelia or mucus (Zoetendal
et al. 2012).
Moving from the small intestine, the caecum is the gate-
way to the colon. In the caecum, relatively long transit times
and the prevailing environmental conditions favour the growth
of fermentative anaerobes that can degrade complex polysac-
charides, notably members of the Firmicutes and Bacteroidetes
phyla (Donaldson, Lee and Mazmanian 2016). In contrast to the
small intestine, the structure and physiology of the colon allows
the survival of a more dense and diverse bacterial community,
which can reach densities of up to 1011 cells per gram of colonic
contents, one of the highest microbial concentrations in nature.
The colon contains two layers of mucus, secreted by goblet cells,
which separate colonic epithelial cells from the bacterial mass.
The inner, firmly attached mucus layer is nearly sterile, whereas
the outer layer is in direct contact with the luminal contents
and can be a rich niche for microbial colonisation (Johansson et
al. 2008, 2010). The luminal and mucosal compartments of the
colon are often colonised by different profiles of bacterial pop-
ulations. In a mouse model, C. albicans cells are visible in the
lumen as well as the mucus layer (Witchley et al. 2019).
The fungal component of the GI tract is less diverse than
its bacterial counterpart (Chehoud et al. 2015; Nash et al. 2017).
Levels of fungal colonisation are lower in the small intestine,
compared to the oral cavity and colon (Schulze and Sonnenborn
2009). Nevertheless, C. albicans can colonise the stomach, small
intestine, caecum, and colon of mice (Witchley et al. 2019). The
human intestinal mycobiota is characterised by a high inter- and
intra-individual variability, which makes it difficult to define a
‘normal’ or healthy GI mycobiota composition (Nash et al. 2017;
Raimondi et al. 2019). However, Ascomycota and Basidiomycota
represent the two dominant phyla in the GI tract (Chehoud et al.
2015; Nash et al. 2017). The most frequently identified genera are
Candida (e.g. C. albicans), Saccharomyces (e.g. S. cerevisiae), Galacto-
myces, Penicillium, Aspergillus, Malasezzia and Debaryomyces. Some
of these fungi may not be true colonisers of the GI tract, but
transient species that are brought by food or the environment.
Consequently, an individual’s lifestyle has a strong influence on
their GI mycobiota and its variability (Auchtung et al. 2018; Rai-
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Figure 6. Oral, vaginal and GI microbiota, and factors that influence C. albicans colonisation of these body sites. The major microbial groups (family level for bacteria
and genus level for fungi) of the healthy oral cavity (only for bacteria) (Bik et al. 2010; Dewhirst et al. 2010), GI tract (Booijink et al. 2010; Arumugam et al. 2011; Zhou
et al. 2013; Villmones et al. 2018) and vagina (Human Microbiome Project Consortium 2012) are listed in decreasing order of abundance. Pie charts indicate the relative
abundance of the phyla in a representative healthy oral cavity and colon (see key for colour code). The fungal component of the oral microbiota is extremely variable,
and many fungi present in this compartment are likely to be transient (see text). Therefore, for the oral cavity, the fungal genera are not presented in descending order
of abundance, and no pie chart is provided. The lower panel summarises factors that influence the degree of C. albicans colonisation (yellow) and likelihood of infection
(brown arrows) of these mucosal surfaces: arrows up, increased likelihood of colonisation/infection; arrows down, decreased likelihood of colonisation/infection. See
text.
Variability between individuals
Each individual has a distinct intestinal microbiota composi-
tion and structure. Many factors such as birth delivery mode,
environmental exposure to colonising microbes, host genetics,
host diet and lifestyle contribute to the unique nature of a given
individual’s intestinal bacterial and fungal microbiota (Qin et al.
2010; Salonen et al. 2014; Mehta et al. 2018), including their car-
riage of C. albicans (Neville, d Enfert and Bougnoux 2015) (Fig. 6).
Variability across lifespan
The mode of childbirth strongly affects the initial structure
of the gut microbial community in neonates (Reyman et al.
2019). Bacteria such as Enterobacter, Haemophilus, Staphylococ-
cus and Veillonella species are found in relatively high abun-
dances in the faecal microbiota of babies born via caesarean
(C)-section (Bäckhed et al. 2015). In contrast, the faecal micro-
biota of vaginally-delivered babies is enriched in Bifidobacterium,
Lactobacillus, Prevotella and Atopobium spp., which are typically
derived from the vagina of mothers (Dominguez-Bello et al.
2010). Babies delivered vaginally appear to be twice as likely to
become colonised by C. albicans compared to those born by C-
section (Parm et al. 2011).
Following birth, the main driver of gut microbiota compo-
sition is infant diet (breastfeeding versus formula milk). The
colon of infants that are exclusively breast-fed is characterised
by high numbers of milk oligosaccharide-utilising Bifidobacterium
species (Yatsunenko et al. 2012; Odamaki et al. 2016; Hill et al.
2017), whereas formula-fed infants tend to possess more diverse
microbiota that are less dominated by bifidobacteria (Rubal-
telli et al. 1998; Klaassens et al. 2009; Lee et al. 2015). Following
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of microbes in a single sample) increases and the microbiota
transitions towards an adult-like composition (Yatsunenko et al.
2012; Schei et al. 2017). Little is known about C. albicans GI pri-
mocolonisation, but this species has been detected in newborns
and infants (Bliss et al. 2008; Schei et al. 2017) and in maternal
milk, suggesting that breastfeeding could be a source of coloni-
sation (Boix-Amorós et al. 2017).
Once established, the adult bacterial microbiota is generally
considered to be quite stable over many decades (Faith et al.
2013), albeit allowing for temporary disruptions by factors such
as antibiotic treatment or inflammation. Every adult has a dis-
tinct microbiota at the species/strain level. Nevertheless, in the
mature adult gut, obligate anaerobes generally predominate, the
microbiota typically containing high levels of Firmicutes and
Bacteroidetes spp. (Qin et al. 2010). There is significant variation
between studies (see Variability due to diet and geography), but Can-
dida spp. are thought to be present in the GI tracts of over half
of adults (Odds 2010; Hoffmann et al. 2013). However, the fungal
mycobiota of the adult GI tract appears to be less stable than the
bacterial microbiota (Dollive et al. 2013).
Further changes in the microbiota occur in the elderly (gener-
ally over 65), possibly associated with altered dietary habits and
living environments, reduced metabolism and immune func-
tion, and increased antibiotic usage (Lovat 1996; Simon, Hollan-
der and McMichael 2015). Accumulating evidence suggests that
old age can be associated with a decrease in ‘beneficial’ bacte-
ria and an increase in ‘harmful’ species (Xu, Zhu and Qiu 2019),
potentially making the elderly population more susceptible to C.
albicans colonisation (Kauffman 2001; Miranda et al. 2009).
Variability arising from host genetics, diet and geography
The composition of the gut microbiota might also be shaped to
some degree by the genetics of the individual, although recent
work has shown that this only has a minor impact (between 1.9%
and 8.1% of gut microbiota variability) compared to other fac-
tors such as environmental exposure and host diet (Rothschild
et al. 2018) Studies of twins have indicated that certain types of
bacteria might be more influenced by host genetics than oth-
ers. For example, the Christensenellaceae family is more likely to
be influenced by host genetics, while Bacteroidetes carriage is
most likely shaped by environmental factors (Simões et al. 2013;
Goodrich et al. 2014).
An individual’s dietary choices have major impacts on the
composition of their bacterial community, and diet is therefore
an important driver of inter-individual variation (Walker et al.
2011; David, Maurice et al. 2014). The main energy sources for
colonic microbiota are complex plant fibres. These can be recal-
citrant to degradation by host enzymes in the small intestine
and therefore pass into the colon relatively intact. Additional
energy sources include residual peptides and host secretions
such as mucus (Derrien et al. 2004, 2008; Hai Li et al. 2015; Van
den Abbeele et al. 2010; Lukovac et al. 2014; Van Herreweghen
et al. 2017; Van den Abbeele, Gérard et al. 2011; Tramontano et al.
2018). The type and availability of these various nutrients exert
selective effects on numerous groups of bacteria. The starkest
difference is between animal-based (high fat and protein con-
tent) and plant-based diets (rich in plant polysaccharides). Plant-
based diets lead to increases in Prevotella species and Firmicutes,
whereas animal-based/lower fibre diets stimulate an increase in
Bacteroides and bile-tolerant species such as Bilophilia and Alis-
tipes (Wu et al. 2011; David, Maurice et al. 2014; De Filippis et al.
2016; Pareek et al. 2019).
Differences in dietary habits between people inhabiting dif-
ferent regions of the world (He et al. 2018), and between those
living in urbanised versus rural settings, are considered to be a
main driver of geographical variation in microbiota composition.
Indeed, the migration of people from rural to westernised set-
tings greatly impacts the composition of their resident intesti-
nal microbiota (Vangay et al. 2018). Those living in less urbanised
societies typically consume greater amounts of dietary fibre and
less meat and processed foods. Consequently, they tend to have
a greater predominance and prevalence of more specialist fibre-
degrading bacteria in their gut. In contrast, people living in
cities or more urbanised countries, are characterised by their
consumption of more refined, high protein and high fat diets,
and they harbour microbial communities with reduced diversity
(Schnorr et al. 2014).
Geographic location also affects the prevailing mycobiota,
especially as many of the fungi detected in the GI tract are not
true colonisers, but only transient species brought in as a result
of different diets/environmental exposures (Auchtung et al. 2018;
Raimondi et al. 2019). For example, Aspergillus oryzae, a species
used to ferment soybeans to make soy sauce, is often present in
the guts of healthy Japanese (Motooka et al. 2017). Also, the rel-
atively high abundance of Penicillium and Debaryomyces spp. in
Sardinian volunteers has been linked with high levels of cheese
consumption in this region (Wu et al. 2020). Interestingly, the GI
tracts of Wayampi Amerindians harbour a relatively high abun-
dance of Candida krusei and S. cerevisiae, and less C. albicans, com-
pared to individuals with more industrialised lifestyles (Ange-
bault et al. 2013). However, the carriage of Candida spp. in the
gut has been negatively associated with amino acid-, protein-,
and fatty acid-rich diets (Hoffmann et al. 2013), which are char-
acteristic of urbanised societies, suggesting that geographically-
related factors other than diet may also affect the likelihood of
Candida carriage in the gut. These may include exposure to envi-
ronmental stressors and pollutants, including antibiotics (Jin
et al. 2017; Karl et al. 2018) (see below).
Variability due to lifestyle and xenobiotics
A range of non-dietary lifestyle factors can also impact the gut
microbiota and its resilience against invading pathogens. For
example, exposure to stress is thought to lower the numbers
of potentially beneficial gut bacteria such as Lactobacillus spp.,
and this has been postulated to have multiple effects on colonic
motor activity via the gut-brain axis (Grenham et al. 2011; Gal-
ley et al. 2014; Murakami et al. 2017). Therefore, Lactobacillus
spp. have been proposed as candidates for probiotic interven-
tion (Bravo et al. 2011). Interestingly, preliminary studies have
shown that Lactobacillus might reduce C. albicans overgrowth
(Drutz 1992; Ceresa et al. 2015; Morais et al. 2017), and reductions
in the prevalence of Lactobacillus spp. in the gut may be asso-
ciated with stress-induced candidiasis (Meyer, Goettlicher and
Mendling 2006; Akimoto-Gunther et al. 2016). Indeed, L. rhamno-
sus has been shown to reduce the capity of C. albicans to damage
epithelial barriers and translocate into the ‘bloodstream’ in an
intestine-on-chip model (Graf et al. 2019; Maurer et al. 2019).
Many xenobiotics interact with, and influence, the gut micro-
biota. In turn, these may increase the risk of developing oppor-
tunistic infections by disrupting colonisation resistance. Antibi-
otics have been the most studied xenobiotics. In addition to
treating the aetiological agent of a disease, long-term broad-
spectrum antibiotics can exert collateral damage upon benefi-
cial indigenous gut bacteria (Dethlefsen et al. 2008; Fouhy et al.
2012; Burdet et al. 2019). This can have the unintended effect
of suppressing colonisation resistance, leading to the outgrowth
of opportunistic pathogens. This includes C. albicans, as antibi-
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GI tract in mice that are normally resistant to colonisation (Fan
et al. 2015). Several studies have attempted to define the mech-
anisms underlying this outgrowth (Guinan et al. 2019; Gutierrez
et al. 2020; Zhai et al. 2020). Cefoperazone-treated mice display
reduced levels of the short-chain fatty acids generated by the gut
microbiota, which enhances C. albicans growth, morphogenesis
and biofilm formation (Guinan et al. 2019). On the other hand,
the outgrowth of C. albicans in antibiotic-treated mice has been
linked to increased levels of carbohydrates, sugar alcohols and
primary bile acids as well as decreases in carboxylic acids and
secondary bile acids (Gutierrez et al. 2020). Although the effect
of antibiotics on the gut mycobiota of healthy humans remains
largely unknown, the administration of antibiotics to immuno-
compromised patients has been associated with decreases in
the diversity of the gut microbiota and marked expansions in
the burdens of pathogenic Candida species (Zhai et al. 2020). The
extent of overall microbiota recovery after cessation of antibiotic
treatment depends on the spectrum of activity of the antibiotic,
the length of time it was administered, and the underlying com-
position of the baseline gut microbiota. In general, the micro-
biota appears to be reasonably resilient to short courses of cer-
tain antibiotics, displaying an ability to recover after treatment
with, for example, ciprofloxacin (Pop et al. 2016) or azithromycin
(Wei et al. 2018). However, recovery is not always complete (Deth-
lefsen et al. 2008; Fouhy et al. 2012).
Attention has also turned towards the susceptibility of the
microbiota to non-antibiotic xenobiotics, many of which are
commonly used drugs (Jackson et al. 2018; Maier et al. 2018; Vich
Vila et al. 2020). Proton pump inhibitors (PPIs) have been the most
studied non-antibiotic xenobiotics (Jackson et al. 2018; Vich Vila
et al. 2020). Some evidence suggests that the use of PPIs increases
the risk of Candida colonisation in intensive care patients (Mojazi
Amiri et al. 2012; Jacobs et al. 2015). Histamine-2 receptor block-
ers also disturb colonisation resistance against opportunistic
infections, primarily C. albicans (Saiman et al. 2001).
Variability associated with illness
Perturbations in the GI tract microbiota are associated with a
multitude of disorders such as Inflammatory Bowel Disease
(IBD), diabetes, obesity, colorectal cancer and cirrhosis. IBD
includes conditions such as Crohn’s disease (CD) and ulcerative
colitis (UC). These diseases can further drive variability within
the gut microbiota. Increasing evidence suggests that people
suffering from some of these conditions display even more
inter-individual variability than healthy controls (Zaneveld,
McMinds and Vega Thurber 2017). IBD patients tend to have
reduced overall microbiota diversity with decreased prevalence
of potentially beneficial Firmicutes lineages such as Faecalibac-
terium prausnitzii. They also have increased levels of opportunis-
tic pathogens such as Enterobacteriaceae, which are better able to
thrive in an inflammatory environment than many other obli-
gately anaerobic gut commensals (Manichanh et al. 2006; Sokol
et al. 2009; Pascal et al. 2017; Franzosa et al. 2019; Lloyd-Price et al.
2019). IBD patients often show a disequilibrium in the diversity
of bacteria and fungi in their GI tracts (Wheeler et al. 2016),
which suggested that Candida spp. might also play a role in IBD
pathogenesis. C. albicans, and the Candida genus in general, are
more abundant in IBD patients (Ott et al. 2008; Kumamoto 2011;
Chehoud et al. 2015; Sokol et al. 2017). Recent data indicate that
Malassezia, rather than Candida, is associated which Crohn’s
disease (Limon et al. 2019). Nevertheless, a positive clinical
response to faecal microbiota transplantation in ulcerative
colitis patients has been associated with high levels of Candida
spp. colonisation before treatment and decreased Candida
abundance in the gut following treatment (Leonardi et al. 2020).
Patients with primary sclerosing cholangitis (PSC) also har-
bour decreased bacterial diversity, while the fungal diversity in
their GI tract is increased (Lemoinne et al. 2020). Patients with
Clostridioides difficile infections that have received a faecal micro-
biota transplant, often show reduced fungal diversity and C. albi-
cans outgrowth in their gut. Indeed, a high abundance of C. albi-
cans in the donor’s gut might compromise the success of the fae-
cal transplantation (Zuo et al. 2018). Alcoholic hepatitis has been
associated with an increase in the abundance of Candida spp.
in the gut mycobiota and a decrease of fungal diversity (Lang
et al. 2020), while an outgrowth of Candida spp. has also been
observed in children suffering from autistic spectrum disorders
(Strati et al. 2017). Therefore, changes in the gut mycobiota are
associated with, and potentially contribute to, a wide range of
pathologies.
Oral cavity
Defining the core oral microbiota for a healthy individual is com-
plicated by the fact that the oral cavity is a primary entry point
for microbes in food and from the environment. Thus, microbes
identified in the oral cavity may be transient, and washed out
through saliva before having any impact upon health, rather
than being active colonisers of this niche. Nevertheless, the oral
cavity does harbour the second largest microbiota, in terms of
diversity, compared to other body sites (Zhou et al. 2013) (Fig. 6).
Variability between individuals
Many of the factors that contribute to the variability of GI tract
microbiota have a similar impact upon the microbiota present
at other body sites, such as the oral environment (Fig. 6).
Variability across lifespan
The development of the oral microbiota in infants is influenced
by their mode of delivery (Lif Holgerson et al. 2011; Dzidic et al.
2018). Infants born by C-section initially have more oral colonis-
ers, such as Staphylococcus, Corynebacterium and Propionibacterium
spp., which are derived from human skin (Dominguez-Bello et al.
2010). In contrast, babies born vaginally have bacterial com-
munities reflecting their mothers’ vaginal bacterial communi-
ties, dominated by Lactobacillus, Prevotella and Sneathia spp. Can-
dida spp. are identified more frequently in the oral microbiota
of newborns that were vaginally born, especially by mothers
whose vagina was colonised by Candida (Al-Rusan, Darwazeh
and Lataifeh 2017).
After 6 months of age, the impact of delivery mode is gradu-
ally eliminated as microbial patterns converge to that observed
for older individuals. The oral microbial communities then
evolve together over time with the host. This applies to both
the oral bacterial and fungal microbiota. However, no consis-
tent pattern has emerged for fungal colonisation, with conflict-
ing results observed between studies (Baley et al. 1986; Cara-
malac et al. 2007; Farmaki et al. 2007; Bliss et al. 2008; Siavoshi
et al. 2013; Filippidi et al. 2014; Stecksén-Blicks et al. 2015; Ward
et al. 2018). Some studies have suggested vertical transmission
from mother to child (Caramalac et al. 2007; Filippidi et al. 2014).
Other studies consider breastmilk to be a source of fungal coloni-
sation, with Malassezia (44%), Candida (19%) and Saccharomyces
(12%) being the main taxa detected within one month of birth
(Boix-Amorós et al. 2017). However, once again, no consistent
pattern has emerged (Darwazeh and al-Bashir 1995; Matee et al.
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Neves et al. 2015; Stecksén-Blicks et al. 2015). The development of
the oral mycobiota can also be influenced by nail biting and fin-
ger sucking, which might enhance the colonisation by microbes
usually found on the skin (e.g. Malassezia spp.) (Dupuy et al.
2014), and the use of pacifiers has also been correlated with
increased fungal colonisation (Darwazeh and al-Bashir 1995;
Mattos-Graner et al. 2001; Zöllner and Jorge 2003).
By the age of three, children have developed a complex oral
microbial community, although they carry higher levels than
older children of Pseudomonadaceae, Moraxellaceae and Enterobac-
teriaceae, which are not usually associated with healthy com-
mensal oral microbiota (Crielaard et al. 2011). The oral bacte-
rial microbiota of healthy adults is marked by increased propor-
tions of Bacteroidetes (Prevotella spp.), Spirochaetes, Actinobac-
teria and Firmicutes (Keijser et al. 2008; Crielaard et al. 2011). The
fungal taxa most frequently isolated from the oral cavity are Can-
dida spp. and S. cerevisiae (foodborne) (Baley et al. 1986; Darwazeh
and al-Bashir 1995; Matee et al. 1996; Mattos-Graner et al. 2001;
Zöllner and Jorge 2003; Kadir, Uygun and Akyüz 2005; Farmaki
et al. 2007; Filippidi et al. 2014; Neves et al. 2015; Ward et al. 2018).
C. albicans is the Candida species most frequently isolated from
the oral cavity, although other species such as C. tropicalis, C. kru-
sei, C. kefyr and C. glabrata have also been detected.
After maturation of the microbiota, the oral cavity is thought
to have the most stable microbial profile among all body sites
(Zhou et al. 2013). Several studies have analysed temporal vari-
ation in the salivary microbiota (Caporaso et al. 2011; David,
Materna et al. 2014; Flores et al. 2014; Belstrøm et al. 2016). This
revealed high variability in the relative abundances of taxa, with,
for instance, greater stability in individuals harbouring a more
diverse tongue community (Flores et al. 2014). As with the GI
tract microbiota, there is evidence that the oral microbiota can
be influenced by birthplace and current geographic residence
(Xu and Mitchell 2003; Wang et al. 2013).
Supragingival, tongue and salivary communities display
strong inter-individual and inter-site differences (Hall et al.
2017). Among all the anatomical sites of the oral cavity, the
supragingival plaque community is distinct from that of the
tongue plaque and the saliva, with high similarity between the
tongue and saliva. The supragingival plaque harbours a bacte-
rial community with much lower diversity compared with that
of the tongue and the salivary communities. Saliva has the high-
est number of bacterial taxa while supragingival plaque has the
lowest. Hall and co-workers (Hall et al. 2017) identified 26 core
taxa, belonging to five phyla (Actinobacteria, Bacteroidetes, Fir-
micutes, Fusobacterium, and Proteobacteria), across all sites.
Few taxa were shared among all sites.
Variability arising from diet
Dietary factors contribute to the variation of oral microbial com-
munities. In general, foods are swallowed quickly after a short
period of mastication. Nevertheless, the introduction or sudden
lack of certain nutrients can cause shifts in the oral microbiota
(Adler et al. 2013; Zheng et al. 2015). For example, microbes that
contribute to folate biosynthesis, such as Streptococcus, increase
after long-term deprivation of fresh fruit and vegetables, which
are rich in folic acid (Zheng et al. 2015). Vegetarians and non-
vegetarians display similar rates of C. albicans carriage in their
oral microflora (Patil et al. 2017). Fungi are introduced to the oral
cavity via food and drink. Therefore, fungi commonly derived
from fermented beverages such as beer are often isolated from
the oral cavity (Fan et al. 2018).
Variability associated with illness
The most common oral conditions include tooth decay, peri-
odontal disease and oral cancer. While many intestinal diseases
have been associated with gut dysbiosis, there is still debate as
to whether oral diseases are correlated with oral microbial diver-
sity. For example, periodontal disease patients display more
diverse and complex oral microbial communities than peri-
implantitis patients (Kumar et al. 2012; Liu et al. 2012). Never-
theless, pathogenic Streptococcus spp. promote caries by lowering
oral pH, which results in the demineralisation of enamel (Ajdić
et al. 2002; Mei et al. 2013; Ito et al. 2019). Interactions between
bacteria and fungi are likely to be of relevance to oral health.
Interestingly, a study assessing Candida load and the bacterial
composition of saliva in a Dutch cohort revealed that a low diver-
sity of salivary microbiota characterised by dominant acidogenic
bacilli (streptococci and lactobacilli) is positively correlated with
elevated Candida burdens and possible overgrowth (Kraneveld
et al. 2012). However, only certain diseases correlate with fungal
colonisation of the oral cavity. These include, but are not limited
to, HIV/AIDS (Cassone and Cauda 2012), cancer treatments (Silk
2014), dental caries (Falsetta et al. 2014) and oral lesions (ulcera-
tions, nodules or granulomas) (Muzyka and Epifanio 2013). All of
these conditions are linked either to the creation of novel niches
that are not naturally present, or to perturbation of immune
function. They are often correlated with Candida overgrowth (C.
albicans in 70–80% cases), leading to oropharangeal candidiasis,




Interactions between the resident microbiota and C. albicans in
the vaginal tract are important for pathogenesis (Fig. 6). The
vaginal bacterial microbiota of healthy reproductive-age women
is generally dominated by Lactobacillus spp. (Ravel et al. 2011).
Lactic acid production by these bacteria contributes to a healthy
vaginal pH that is commonly lower than 4.5 (Ravel et al. 2011).
The vaginal bacterial microbiota can be further sub-classified
into five main community state types (CSTs): CST-I (Lactobacil-
lus crispatus-dominated); CST-II (L. gasseri-dominated); CST-III (L.
iners-dominated); and CST-V (L. jensenii-dominated) (Ravel et al.
2011). The CST-IV state is extremely diverse compared to the
other types, comprising anaerobes and species linked to bac-
terial vaginosis (BV). CST-IV has been further divided into sub-
groups: CST-IVA (containing some lactobacilli); CST-IVB (high
prevalence of Atopobium spp.); CST-IVC (Gardnerella subgroup A-
dominated); and CST-IVD (Gardnerella subgroup C-associated)
(Gajer et al. 2012; Albert et al. 2015). Women can transition
between these CST states, for example, during menses (Gajer
et al. 2012). CST-I has been associated with C. albicans colonisa-
tion (Sarah E Brown et al. 2019), but more studies are required to
fully understand the complexity of the vaginal microbiota and
its potential association with disease.
Less is known about the mycobiota of the human vagina.
Culture-dependent studies indicate that C. albicans is the most
abundant fungal species, although its abundance has been
shown to vary according to lifestyle, age, ethnicity, hygiene
habits and contraceptive methods (Fischer 2010; Wei, Feng and
Luo 2010; Fischer and Bradford 2011; Shaaban et al. 2015; Don-
ders et al. 2017, 2018). Indeed, intrauterine contraceptive sys-
tems have been reported to be associated with a rise in C. albi-
cans colonisation, while progesterone-only pills result in lower
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the relatively low sensitivity of conventional culture approaches,
these studies may underestimate the true fungal diversity of the
vagina (Guo et al. 2012; Drell et al. 2013). Using 18S rRNA gene
sequencing, Guo and co-workers demonstrated that the healthy
vaginal mycobiota was mainly composed of Ascomycota (∼70%
relative abundance), with the Candida genus dominating, and C.
albicans as the main species. Basidiomycota were also detected,
but with a lower proportional abundance (Guo et al. 2012). These
results were confirmed using ITS1 pyrosequencing (Drell et al.
2013). Taking these findings together, the most abundant fungi
in the healthy vaginal tract appear to be C. albicans, S. cerevisiae
and C. tropicalis (Guo et al. 2012). Recent data indicate an associ-
ation between the type of Lactobacillus species present and the
likelihood of Candida colonisation (Tortelli et al. 2020).
Variability associated with age and pregnancy
The vaginal bacterial microbiota is influenced by oestrogen lev-
els and is most stable when these are high (Gajer et al. 2012)
(Fig. 6). Prepuberty is characterised by a bacterial microbiota
comprised of anaerobes, diphtheroids, lactobacilli, streptococci,
Staphylococcus epidermidis, and Escherichia coli (Hammerschlag
et al. 1978). During puberty, increased oestrogen stimulates
thickening of the glycogen-rich vaginal epithelium and estab-
lishes a vaginal microbiota dominated by lactobacilli (Miller
et al. 2016). High oestrogen levels in reproductive women cre-
ate unique features for the vaginal mucosa (Kalia, Singh and
Kaur 2020), inducing a tolerogenic immune repertoire through
immunomodulation of the neutrophil response (Willems et al.
2020). When glycogen is degraded by host α-amylases, products
such as maltose and maltotriose foster the growth of Lactobacil-
lus, leading to a reduced vaginal pH (Spear et al. 2014).
Lactobacillus spp. typically dominate the vaginal microbiota
during pregnancy, and increased levels of these bacteria were
reported in Lactobacillus-dominated CSTs compared to non-
pregnant women (Aagaard et al. 2012; Romero et al. 2014; Mac-
Intyre et al. 2015; Freitas et al. 2017). During pregnancy, the
microbiota is also characterised by a lower occurrence of Molli-
cutes, and by members of the orders Clostridiales, Bacteroidales,
and Actinomycetales (Aagaard et al. 2012; Freitas et al. 2017).
Sampling six weeks postpartum revealed that bacterial diver-
sity increases following birth and the vaginal microbiota readily
assumes CST-IV (MacIntyre et al. 2015).
Fluctuations in oestrogen levels probably underlie variations
in the abundance of C. albicans. Indeed, oestrogen injection is
required to promote C. albicans colonisation of the vagina in rats
and mice (Cheng, Yeater and Hoyer 2006). This is probably linked
to the stimulatory effects of oestrogen upon C. albicans morpho-
genesis (White and Larsen 1997; Tarry et al. 2005). In humans,
rising oestrogen levels during pregnancy has also been associ-
ated with an increase in C. albicans colonisation (Goplerud, Ohm
and Galask 1976), which can potentially lead to premature birth
(Roberts et al. 2011).
Postmenopausal women are also more likely to display a
CST-IV microbiota (Brotman, Shardell et al. 2014). Menopausal
women frequently experience a loss of lactobacilli and an
increased vaginal pH (Brotman, Shardell et al. 2014; Gliniewicz
et al. 2019). This elevation in vaginal pH, combined with an
increase in vaginal glycogen levels, may contribute to the
reduced incidence of VVC observed after the menopause (Hillier
and Lau 1997; Spinillo et al. 1997). The reduced levels of oestro-
gen may also explain the decreased rates of VVC in post-
menopausal women (Nwokolo and Boag 2000). Consequently,
hormone replacement therapy (HRT) is a risk factor for VVC
in these women (Fischer and Bradford 2011). HRT can restore
a Lactobacillus dominated microbiota, similar to that of pre-
menopausal women (Gliniewicz et al. 2019), and this treatment
increases the likelihood of postmenopausal women succumbing
to VVC (Fischer and Bradford 2011). However, more comprehen-
sive studies are needed for a better understanding of the rela-
tionship between the overall vaginal mycobiota and health and
disease.
Variability relating to geography and ethnicity
Independent of geography, the vaginal microbiota of women is
dominated by Lactobacillus (Anukam et al. 2006; Shi et al. 2009;
Zhou et al. 2010; Ravel et al. 2011; Pendharkar et al. 2013; Albert
et al. 2015; Madhivanan et al. 2015). Nevertheless, the dominat-
ing species of the Lactobacillus genus may differ between geo-
graphical regions. Similar rates of vaginal colonisation by Can-
dida spp. (11–17%) have been reported for asymptomatic women
from European, South American and Middle Eastern countries
(Gonçalves et al. 2016). However, VVC rates differ significantly
for symptomatic women around the world, ranging from 12% to
57%, and most cases are caused by C. albicans (Gonçalves et al.
2016).
Regarding ethnic differences, Asian and Caucasian women
from North America are mainly colonised by Lactobacillus spp.
(CST-I, II, III and V), whereas black and Hispanic women are more
likely to be colonised by CST-IV communities (Ravel et al. 2011).
Women of African, American and European ancestry are more
likely to be colonised by L. iners and L. crispatus, respectively (Fet-
tweis et al. 2014). However, the basis for these differences is not
clear (Gupta, Kakkar and Bhushan 2019). The evidence for differ-
ent VVC rates between ethnic groups is limited (Wei, Feng and
Luo 2010). Further studies would be required to define whether
significant differences exist, and to parse apart the basis for any
apparent differences.
Variability arising from lifestyle and xenobiotics
A number of factors influence the vaginal microbiota and, conse-
quently, may predispose women to infection or aid in preventing
infection (Fig. 6). The effects of antibiotics on the microbiota of
women with vaginal infections are well studied. Metronidazole
treatment of women with BV has been shown to increase preva-
lence of Lactobacillus spp. (Mayer et al. 2015). Similarly, the vaginal
microbiota becomes dominated by L. iners when azithromycin
is administered to treat Chlamydia trachomatis (Tamarelle et al.
2020). The composition of the lactobacilli community can shift
in response to antibiotics, since vaginal Lactobacillus spp. have
varying antibiotic sensitivity profiles (Melkumyan et al. 2015).
Pregnant women frequently become colonised with Staphylococ-
cus when receiving antibiotic treatment (Stokholm et al. 2014).
It is well known that antibiotic treatments predispose individu-
als to VVC if they are already colonised with Candida spp. (Sobel
2007).
Not much is known regarding the impact of diet on the vagi-
nal bacterial microbiota. Individuals consuming fibre-rich diets
are less likely to have BV-associated microbiota (Shivakoti et al.
2020). Ingestion of micronutrients such as the zwitterion betaine
(an osmolyte and methyl donor) may result in a microbiota
that is predominantly lactobacilli (Tuddenham et al. 2019). In
addition, smoking reduces vaginal lactobacilli (potentially via
amines, anti-oestrogenic effects and bacteriophage induction)
and increases the probability of acquiring a CST-IV microbiota
(Brotman, He et al. 2014). As the vaginal microbiota influences
the vaginal mycobiota (Sobel 2007), these effects are likely to
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Translational opportunities
Given the impact that the microbiota appears to have on suscep-
tibility to Candida infections, there are clear potential therapeu-
tic benefits to bolstering our microbial communities at various
body sites. Probiotics provide a means of altering the microbiota.
Probiotics are defined as ‘live microorganisms that, when adminis-
tered in adequate amounts, confer a health benefit on the host’ (Hill
et al. 2014). Currently, robust evidence for clinical efficacy is lim-
ited to a relatively narrow set of conditions. However, there is
clear potential to widen this applicability to IBD, for example
(Rondanelli et al. 2017). Interactions between the microbiota and
host are thought to play key roles in Candida colonisation and
pathogenesis, and therefore, live biotherapeutic products (LBPs)
that exert anti-Candida effects are worthy of further study. (LBPs
are products containing live microbes that are used to prevent or
treat a medical condition.) Some are under development (Poupet
et al. 2019). These have the potential to dramatically amelio-
rate the economic and health burden imposed by this fungus
and reduce the risk of vulnerable individuals to Candida infec-
tions. Several types of patient cohort may benefit from such an
approach.
Premature neonates are among those most at risk of develop-
ing systemic Candida infections. Compared to full-term healthy
babies, premature newborns have an altered microbiota and can
be colonised by opportunistic pathogens (Hill et al. 2017; Kor-
pela et al. 2018). In addition to weakened colonisation resis-
tance, their immature immune system places them at risk of
late-onset sepsis caused by C. albicans, which has colonised
their GI tract through vertical transmission from their moth-
ers, or from the hospital environment (Bliss et al. 2008). Sup-
plementation with a Lactobacillus probiotic (L. rhamnosus and
L. reuteri) results in lower GI tract colonisation of Candida spp.
compared to controls (Manzoni et al. 2006; Romeo et al. 2011).
L. reuteri was found to be as effective as the antifungal nys-
tatin in preventing candidaemia (Oncel et al. 2015). Replac-
ing prophylactic antifungal treatments with LBP-based therapy
would have the advantage of reducing the selection for anti-
fungal drug resistance. Additionally, LBPs may benefit prema-
ture neonates by preventing GI symptoms such as regurgitation,
vomiting and abdominal distension (Indrio et al. 2008; Rougé
et al. 2009; Romeo et al. 2011), while reducing hospitalisation time
(Romeo et al. 2011). Consequently, the use of LBPs for premature
neonates may help decrease their risk of developing nosocomial
infections.
HIV positive individuals are another group at high risk of
developing C. albicans infections, especially oropharyngeal can-
didiasis (Patil et al. 2018). Administration of probiotic strains with
anti-Candida activity could prevent the development of such
infections by reducing levels of fungal colonisation (Hu et al.
2013).
Studies have shown that LBPs are more successful than
placebos at preventing recurrence of vulvovaginal candidia-
sis (Vladareanu et al. 2018). Furthermore, therapies that com-
bine LBPs with azoles have been shown to improve drug effi-
cacy by restoring the local bacterial community (Kovachev and
Vatcheva-Dobrevska 2015; Russo et al. 2019). Increasing the effi-
cacy of the antifungal drug in this way may allow drug doses to
be reduced.
Taken together, current evidence is encouraging and sug-
gests that probiotics can be used to prevent C. albicans infections
in vulnerable cohorts. However, further studies are required to
identify optimal LBP candidates, and to understand the under-
lying mechanisms of action that result in clinical efficacy.
THE FUNGUS-HOST-MICROBIOTA INTERPLAY
The previous sections describe the multifaceted nature of C.
albicans interactions with the host, how antifungal immunity
influences these interactions, and how the microbiota is closely
related to host physiology and impacts C. albicans colonisation.
These tripartite interactions between host, fungus and micro-
biota are incredibly complex and strongly influence the likeli-
hood and outcomes of Candida infections. Here we discuss the
nature of interdependencies within the fungus-host-microbiota
interplay and their impact on health and Candida infections, in
particular.
Synergistic and antagonistic interactions between
kingdoms
Many researchers have focused on antagonistic interactions
between C. albicans and bacteria species because these could
potentially be exploited in therapeutic approaches (see Impact of
a changing microbiota on the Fungus-Host-Microbiota interplay and
Translational opportunities). However, it is estimated that approx-
imately 30% of all Candida bloodstream infections are polymi-
crobial and involve both fungi and bacteria (Klotz et al. 2007).
This suggests that synergism can occur between C. albicans and
certain bacterial species (Fig. 7). [In this context, ‘synergism’
describes polymicrobial interactions during which one microor-
ganism promotes colonisation or infection by another (Brogden,
Guthmiller and Taylor 2005)].
Candida albicans interacts with different types of resident
microorganisms depending on the body site (see The Microbiota).
Candida albicans synergises with various streptococcal species
that are abundant in the oral cavity, through physical interac-
tions that enhance bacterial growth and adhesion, lead to more
pronounced biofilm formation and, in some cases, increase fun-
gal invasion (Silverman et al. 2010; Diaz et al. 2012; Metwalli et al.
2013; Xu et al. 2016; Koo, Andes and Krysan 2018; Vila et al. 2020).
Molecules involved in these physical interactions include bac-
terial adhesins (Holmes, McNab and Jenkinson 1996; Silverman
et al. 2010), specific fungal surface proteins (Holmes, McNab and
Jenkinson 1996; Dutton et al. 2014; Xu et al. 2017), and com-
ponents of the extracellular polysaccharide matrix produced
in biofilms (Falsetta et al. 2014). Communication within mixed
biofilms involves bacterial and fungal quorum sensing systems
that influence the expression of virulence factors and bacterial
metabolism (Sztajer et al. 2014; He et al. 2017; Kim et al. 2017).
In addition to this direct synergism, streptococcal co-infection
stimulates complex immune reactions that promote the expres-
sion of proinflammatory cytokines and enhanced tissue inflam-
mation in a murine model of C. albicans thrush (Xu et al. 2014).
The clinical importance of these synergistic interactions is sug-
gested by co-colonisation of bacteria with fungi in oral diseases
such as childhood caries, periodontitis, and denture stomati-
tis (O’Donnell et al. 2015). Furthermore, a causal relationship
between bacterial-fungal co-infection and disease severity has
been demonstrated for caries in a rat model (Falsetta et al. 2014).
Fungal colonisation also affects oral microbiota composition,
which encourages invasive infection (Bertolini et al. 2019).
The synergistic cross-kingdom interactions between C. albi-
cans and Staphylococcus aureus have been comparatively well
studied (Carolus, Van Dyck and Van Dijck 2019) (Fig. 7). Staphy-
lococcus aureus can bind to C. albicans hyphae, which indirectly
enhances the attachment of the bacterium to abiotic surfaces
and promotes the formation of mixed biofilms with increased
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Figure 7. The interplay between C. albicans and certain bacterial present in human microbiotas. The growth of C. albicans in mucosal niches is generally constrained by
the local bacterial microbiota via colonisation resistance. However, specific interactions with certain bacteria present in the vagina, oral cavity and/or GI tract influence
the growth and/or virulence of C. albicans more directly. These interactions can be antagonistic (i.e. reduce the growth and virulence of the fungus) or synergistic (i.e.
enhance the growth or virulence of the fungus). Anaerobic bacteria antagonise C. albicans colonisation by mechanisms that include the production of short chain fatty
acids. S. enterica Typhimurium kills C. albicans hyphae by injecting effectors into the fungus via the SopB translocase. Lactobacilli antagonise C. albicans colonisation
acidifying the local environment which reduces filamentation, and by generating metabolites that enhance IL-22-mediated immunity. E. faecalis blocks yeast-hypha
morphogenesis and biofilm formation using EntV. Interactions between C. albicans and P. aeruginosa mutually enhance their virulence via cross-talk involving ethanol
production by the fungus, which promotes toxic phenazine production by the bacterium, and this in turn promotes alcohol production by C. albicans. S. aureus binds
C. albicans hyphae and promotes biofilm formation and antimicrobial resistance. Furthermore, co-infection with S. aureus significantly enhances the lethality of C.
albicans. Streptococci block the formation of C. albicans hyphae via the diffusible factor, SDSF, but potentially co-exist as commensals with C. albicans. See text.
Jabra-Rizk 2009; Harriott and Noverr 2010; Peters et al. 2010; Har-
riott and Noverr 2011; Kong et al. 2016; Kean et al. 2017). Even
more striking, though, is the enhanced lethality observed fol-
lowing co-infection in a mouse model (Peters and Noverr 2013).
A synergistic enhancement of virulence occurs, independent of
the ability of C. albicans to form filaments (Nash et al. 2016). This
synergy is driven by an augmented host immune response (Nash
et al. 2016, 2014; Peters and Noverr 2013). In addition, the pres-
ence of C. albicans increases the expression of staphylococcal vir-
ulence factors by modifying the environment (Todd et al. 2019;
Todd, Noverr and Peters 2019). Significantly, this synergistic vir-
ulence depends on the Candida species involved, and was not
observed for the closely related, but less virulent species, Can-
dida dubliniensis.
Some relationships are difficult to place within a dichoto-
mous scheme of synergism or antagonism. In some cases, dif-
fusible molecules underlie inter-kingdom interactions (Deveau
et al. 2018) as well as microbiota-induced immunomodula-
tion of the host (Blacher et al. 2017). Most bacterial molecules
target C. albicans virulence factors. Salmonella enterica serovar
Typhimurium uses SipB translocase to inject SopB effectors and
induce killing of the fungal hypha (Kim and Mylonakis 2011).
Enterococcus faecalis restricts biofilm development by prevent-
ing yeast-to-hypha transition via the bacteriocin inhibitor EntV
(Graham et al. 2017). Streptococcus mutans prevents hypha forma-
tion by targeting HWP1 (a hyphal-specific gene) using Strepto-
coccus Diffusible Signal Factor (SDSF), a fatty acid. (Vı́lchez et al.
2010). These molecules do not act on the yeast form, indicating
a potential propensity for commensal co-existence.
The host responds to, and influences, some fungal-bacterial
interactions. This has been observed for interactions between C.
albicans and Pseudomonas aeruginosa, which engage in an inter-
active molecular dialogue that leads to mutual enhancement
of their virulence (Chen et al. 2014) (Fig. 7). C. albicans produces
ethanol, which favours the production of more toxic classes
of phenazines by P. aeruginosa, such as pyocyanin, phenazine
methosulfate and phenazine-1-carboxylate. As well as inhibit-
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induce C. albicans to produce more ethanol by compromis-
ing mitochondrial functionality (Morales et al. 2013; Lindsay
et al. 2014). Ethanol reduces the ability of macrophages to
clear P. aeruginosa (Greenberg et al. 1999), while phenazines
cause damage to respiratory epithelial tissues (Rada and Leto
2013). The mammalian host contributes actively to this inter-
play by responding to phenazines via the Aryl hydrocarbon
Receptor (AhR) to enhance antimicrobial defences (Moura-Alves
et al. 2014). Significantly, there is a strong association between
ethanol production by Candida and the development of oral can-
cer (Alnuaimi et al. 2016).
The mammalian AhR is a multi-class receptor that modu-
lates disease resistance (by activating IL-17A/IL-22 production)
and disease tolerance (via TGF β activated Treg cell differentia-
tion) (Cheng et al. 2010; Zelante et al. 2013; Bessede et al. 2014)
(see Adaptive immunity). AhR functions within the indoleamine
2,3-dioxygenase 1 (IDO1)-catalysed pathway that converts tryp-
tophan to L-kynurenine (Bessede et al. 2014). This pathway plays
a dual role as microbial commensals use it to enhance host
resistance, while pathogenic populations exploit it to dampen
immune responses (Cheng et al. 2010; Zelante et al. 2013) (Fig. 7).
Lactobacilli can switch their usage of carbon sources from
sugar to tryptophan and utilise this pathway to initiate strain-
and location-specific host effects that protect against C. albi-
cans infection (Zelante et al. 2013). L. reuteri produces indole-3-
aldehyde (3-IAld), which binds AhR and triggers the production
of IL-22 in the gut. Meanwhile, L. acidophilus utilises the AhR/IL-
22 axis against C. albicans in the vagina. However, C. albicans
is able to switch tryptophan degradation mechanisms from L-
kynurenine to 5-hydroxyltryptophan, which inhibits IL-17 pro-
duction and impairs the host response against infections (Cheng
et al. 2010). These examples illustrate the complexity of interac-
tions between the fungus, the host and the microbiota.
Impact of a changing microbiota on the
Fungus-Host-Microbiota interplay
The host microbiota contributes to anti-Candida defences
through colonisation resistance. Consequently, perturbations of
the healthy oral, gut and vaginal microbiota can predispose the
host to C. albicans infection (see The Microbiota) (Fig. 8). However,
C. albicans is not a passive player in these interactions (see The
Fungus). For example, the fungus actively promotes oral micro-
biota perturbations under conditions of immunosuppression
by increasing the prevalence of enterococci, which negatively
impacts the integrity of the epithelial barrier and enhances C.
albicans invasion (Bertolini et al. 2019). The complexity of inter-
actions between the fungus, host and microbiota are also evi-
dent in the vagina, where high oestrogen levels promote Lac-
tobacillus spp. colonisation, and affect C. albicans morphogene-
sis, thereby influencing the risk of C. albicans colonisation (see
Vaginal mucosa). Colonisation resistance against C. albicans arises
though a number of synergistic mechanisms, many of which tar-
get fungal virulence traits or modulate the host’s response.
Several members of the gut microbiota that contribute to
colonisation resistance against C. albicans produce short chain
fatty acids (SCFAs). Antibiotic treatment leads to a reduction
in colonic SCFAs and, consequently, an increase in the sus-
ceptibility of mice to C. albicans infection (Noverr and Huffna-
gle 2004; Guinan et al. 2019). Butyrate, in particular, has a pro-
found impact on C. albicans growth, biofilm and hypha forma-
tion (Nguyen et al. 2011; Guinan et al. 2019). In the colon, such
effects are unlikely to be mediated by weak acid stress (Rams-
dale et al. 2008) given that the ambient pH of this niche is above
the pKa for this SCFA. Rather, butyrate perturbs iron homeosta-
sis (Cottier et al. 2015) and inhibits the metabolic activity of the
fungus (Nguyen et al. 2011; Guinan et al. 2019) via Mig1 regulation
of HGT16, which encodes a putative glucose transporter (Cot-
tier et al. 2017). In vitro studies have demonstrated that SCFAs
impair C. albicans morphogenesis and biofilm formation, in part
by reducing the ambient pH (Noverr and Huffnagle 2004; Nguyen
et al. 2011; Guinan et al. 2019). Similarly, lactic acid, generated
by lactobacilli, maintains an acidic vaginal pH that inhibits C.
albicans morphogenesis (Köhler, Assefa and Reid 2012). Although
Lactobacillus spp. also produce hydrogen peroxide, it is believed
that lactic acid is the main basis for anti-Candida activity in the
vagina (Strus et al. 2005; Köhler, Assefa and Reid 2012).
Both hypha and biofilm formation promote the pathogenic-
ity of C. albicans. The formation of C. albicans biofilms depends
upon the yeast-to-hypha transition, and is a significant clinical
challenge (see Virulence factors). Some members of the micro-
biota have been shown to hinder C. albicans morphogenesis and
biofilm formation via secreted enzymes (Allonsius et al. 2019) or
other products (Jarosz et al. 2009; Vı́lchez et al. 2010; James et al.
2016; Oliveira et al. 2016; Hager et al. 2019; Jang et al. 2019). Nev-
ertheless, C. albicans can form polymicrobial biofilms with some
members of the oral and gut microbiota, which display elevated
drug and host resistance and can strongly influence clinical out-
comes (Harriott and Noverr 2011; Fox et al. 2014; Cavalcanti et al.
2015).
Competition for adhesion sites and nutrients, especially glu-
cose, by members of the microbiota also contributes to coloni-
sation resistance against C. albicans in the gut, vagina and oral
cavity (Boris et al. 1998; Basson 2000; Graf et al. 2019). L. rhamnosus
GG is a common gut and oral isolate (Ahrné et al. 1998) that has
been shown to prevent C. albicans-induced damage and invasion
through both nutrient depletion and blocking of adhesion sites
(Mailänder-Sánchez et al. 2017). L. rhamnosus can also reduce C.
albicans proliferation and induce shedding from the epithelial
barrier, thereby preventing invasion of the fungus into the tissue
(Graf et al. 2019). Interactions between the microbiota, including
microbial-associated factors, and the host immune system help
to regulate C. albicans and prevent dissemination.
The microbiota also influences the colonisation of C. albi-
cans indirectly by influencing host functionality. Macrophages
exposed to microbiota-produced butyrate are more efficient at
phagocytosing C. albicans cells, and they produce increased lev-
els of nitric oxide, which enhances eradication of the pathogen
(Nguyen et al. 2011). In response to butyrate generated by
the microbiota, colon epithelial cells express the AMP, LL-37
(Schauber et al. 2003), which exerts candidacidal effects (see
Innate antifungal responses). These host cells also activate LL-
37 production in response to microbiota-induced hypoxia via
HIF-1α (Hypoxia Induced Factor 1α) (Fan et al. 2015). Blautia pro-
ducta and Bacteroides thetaiotaomicron, both common members
of the human gut microbiota, promote colonisation resistance
and eliminate C. albicans by stimulating LL-37 production in mice
(Fan et al. 2015). Colonisation resistance against C. albicans is also
provided by IL-22, which is produced by the host and induced
by lactobacilli (Zelante et al. 2013). In addition, L. rhamnosus
GG modulates the inflammatory response of epithelial cells
by reducing IL-1α and GM-CSF production (Mailänder-Sánchez
et al. 2017). By limiting the C. albicans-induced proinflamma-
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Figure 8. The complexity of fungus-host-microbiota interactions is dramatically increased by variability between C. albicans clinical isolates, between individuals, and
in their microbiotas. Fungal variability arises through significant genetic and phenotypic variation between clinical isolates of C. albicans. The immune-competence
of individuals varies significantly depending on their genetics, age and lifestyle. Furthermore, the microbiotas of the GI tract, oral cavity and vagina can each vary
dramatically, depending on the age and health of the individual, and their diet, possible medications and life circumstances. Therefore, variation in each of the three
elements of the fungus-host-microbiota interplay strongly influences the susceptibility of an individual to C. albicans infection as well as the outcome of that infection.
See text.
IL-1β), lactobacilli can alleviate symptomatic vulvovaginal can-
didiasis while sustaining an antifungal immune response (Wag-
ner and Johnson 2012). Similarly, L. crispatus reduces epithelial
TLR2/4 expression and IL-8 levels in the presence of C. albicans,
but maintains antifungal activity by increasing β-defensin pro-
duction (Rizzo, Losacco and Carratelli 2013). Clearly, the changes
in the microbiota strongly influence the iterative interactions
between fungus, host and microbiota. Specific probiotic bacte-
ria, including Bifidobacterium breve, L. rhamnosus, and Lactobacil-
lus casei can also modulate specific PRR ligand- and C. albicans-
induced cytokine responses (Plantinga, van Bergenhenegouwen
et al. 2012).
Impact of patient variability upon the
Fungus-Host-Microbiota interplay
The nature of an individual affects the types and outcomes
of fungal-microbiota interactions directly and indirectly by: (i)
genetic determinants that influence immune responses; (ii) per-
sonal environment and lifestyle, which affect the microbiota
and (iii) iatrogenic interventions that target the microbiota or
host response (Fig. 8). As outlined above, the microbiota is
critical for colonisation resistance, leading to host protection,
but on the other hand, certain combinations of opportunistic
pathogens synergise to promote infection (see Synergistic and
antagonistic interactions between kingdoms). It is well known that
diet strongly influences the human gut microbiota (David, Mau-
rice et al. 2014; Jeziorek, Frej-Mądrzak and Choroszy-Król 2019).
Fundamental differences in diet, and possibly also exposure to
microbes, are the most likely reason for the observed differences
in C. albicans colonisation rates between industrialised and rural
countries, which can differ by over 10-fold (Angebault et al. 2013)
(see Gastrointestinal (GI) tract). Antibiotic treatments are probably
the most common iatrogenic intervention that directly affects
the microbiota, and one of the main predisposing factors to
candidiasis in general. More specific iatrogenic factors include
oral contraceptives and dental prostheses, which alter the local
mucosal environment and thereby promote vaginal and oral
candidiasis, respectively (Mothibe and Patel 2017; Jacob et al.
2018).
A healthy immune system is crucial for protection against
fungal infections (see The Host). Individuals vary in their sus-
ceptibility to C. albicans infection because of genetic differences
that affect susceptibility, and the existence of coexisting mor-
bidities in some individuals. Genetic variations in key recep-
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risk of Candida infections (see Variability amongst individuals).
For instance, monogenic primary immunodeficiency syndromes
highly predispose an individual to haematogenously dissem-
inated candidiasis and mucosal candidiasis (e.g. OPC, skin,
nails). However, the genetic mutations defined to date do not
explain the observed variation in susceptibility to candidiasis
within not-at-risk subjects. Phenotypic variation occurs also in
healthy individuals. For instance, if primary immune cells from
healthy immunocompetent individuals are challenged with C.
albicans in vitro, different outcomes are observed due to varia-
tion in their immune cell populations (Misme-Aucouturier et al.
2017). This can arise through genetic variation at the CR1 locus,
which encodes a master regulator of C. albicans-specific immune
responses (Piasecka et al. 2018). Thus, inter-individual variabil-
ity in innate and adaptive responses against Candida spp. are
likely to influence the degree of host-mediated damage during
infection (Alvarez-Rueda et al. 2020). Consequently, understand-
ing the basis of subject-to-subject diversity, and how this affects
Candida pathogenicity, is likely to prove important for prevention
and therapeutic strategies.
Comorbidities and treatment of other diseases can also
affect a patient’s susceptibility to C. albicans infection (see C.
albicans commensalism and pathogenicity). Uncontrolled diabetes,
for example, favours both bacterial and yeast infections due
to metabolic alterations and impaired antimicrobial activity
(Rodrigues, Rodrigues and Henriques 2019). Admission to an
ICU, medical surgery, hematopoietic stem cell transplantation,
and the use of external devices are independent risk factors for
candidaemia and, together with the duration of hospitalisation,
affect the mortality rates for candidiasis infections (Ortega et al.
2005; Das et al. 2011; Falcone et al. 2017; Poissy et al. 2020). These
patients are commonly immunocompromised, either as a result
of their primary disease, or through treatment. For example, OPC
is a hallmark of HIV positive individuals and cancer patients
(Samaranayake 1992; Redding et al. 1999). Moreover, as men-
tioned, dysregulated innate immunity is associated with fail-
ure to clear Candida spp., for example in neutropenic patients or
neutrophil-related disorders (Nucci et al. 1997; Desai and Lion-
akis 2018). Glucocorticoids (Fan et al. 2012) and chemotherapy
(Teoh and Pavelka 2016) weaken the host defence and increase
the risk for invasive candidiasis.
Impact of fungal variability on the
Fungus-Host-Microbiota interplay
Variability in C. albicans-host relationships is driven by the fun-
gus as well as the host and its microbiota (Fig. 8). Clinical iso-
lates of C. albicans display a high degree of genetic and phe-
notypic diversity (see Candida albicans epidemiology and variabil-
ity). This fungal diversity can be observed at the genetic level
(Tavanti et al. 2006; Cavalieri et al. 2017; Schönherr et al. 2017) as
well as the transcriptional level (Thewes et al. 2008). The vari-
ation impacts multifarious aspects of C. albicans biology, such
as stress and nutrient responses, and virulence properties such
as morphogenesis, adhesion and invasion, that consequently,
influence initial host-pathogen interactions, as well as colonisa-
tion and infection (see The Fungus). Therefore, it is not surpris-
ing that fungal variation affects the fitness of a given C. albicans
strain in the host, and also disease outcome (Thewes et al. 2007,
2008; Cavalieri et al. 2017; Schönherr et al. 2017; Kirchner et al.
2019).
In principle, C. albicans strains can be classified on the basis
of their virulence, rather than their epidemiological relationship.
Comparative studies of various C. albicans isolates have identi-
fied genes whose expression or lack of expression strongly influ-
ences the virulence potential of these strains. Examples include
EFG1, encoding a key transcription factor involved in morpho-
genesis (Hirakawa et al. 2015), and DFG16, encoding a pH sen-
sor (Thewes et al. 2007). Strains displaying reduced expression
of EFG1 or DFG16 display reduced virulence in mouse models of
systemic infection (Thewes et al. 2007; Hirakawa et al. 2015). Even
the development of hemizygosity at the EFG1 locus is sufficient
to promote commensalism, rather than pathogenicity, in C. albi-
cans (Liang et al. 2019).
A number of studies have highlighted the significance of vari-
abilities between C. albicans isolates. The three C. albicans iso-
lates, SC5314, 101 and ATCC10231 are all able to form hyphae.
Nevertheless, SC5314 displays enhanced tissue invasion com-
pared to ATCC10231 and 101 (Thewes et al. 2007; Schönherr et al.
2017), resulting in higher virulence. The strain SC5314 triggers
rapid neutrophil recruitment and the production of proinflam-
matory cytokines leading to fungal clearance of the oral mucosa.
In contrast, strains with lower virulence induce slower and
weaker immune responses, which lead to fungal persistence
(Schönherr et al. 2017). Similar results have been observed in a
murine model of vaginal colonisation, where a less immunos-
timulatory C. albicans strain is able to persist over five weeks, in
contrast to SC5314, which is cleared by week three (Rahman et al.
2007). The genetic background of C. albicans also influences sur-
vival in the phagosome (Tavanti et al. 2006; Cavalieri et al. 2017),
the relative importance of specific PRRs for fungal clearance in
vivo (Marakalala et al. 2013) and even the polarisation of the
immune response (Cavalieri et al. 2017). Clearly, the intraspecies
diversity of C. albicans has major consequences for the outcome
of host-pathogen interactions.
NEW CHALLENGES
Elaborating the complexity of the microbiota
Meta-omics
The ability to define the complexity of relevant microbiotas
rapidly and accurately represents a major challenge. It is vital
that we address this challenge to establish phenotypic asso-
ciations with specific members of the microbial community.
Meta-omics, which refers to culture-independent functional and
sequence-based analysis of the collective microbial genomes,
transcriptomes, proteomes or metabolomes in a given sample
(Handelsman et al. 1998; Riesenfeld, Schloss and Handelsman
2004), includes a powerful set of approaches to achieve this.
To date, DNA sequence-based studies have often been based
on the analysis of amplicons generated from the microbial
community with specific primers that are typically targeted
towards bacterial 16S ribosomal RNA genes, and fungal 18S
rRNA genes or internal transcribed spacer (ITS) regions. These
approaches can provide comprehensive overviews of microbiota
compositions, without directly assessing functional capabili-
ties. However, the continuing development of DNA sequencing
and genome analysis bioinformatics tools is permitting more
widespread use of full shotgun metagenomics instead. This
approach does not rely on amplification of marker genes since
the extracted DNA is sequenced directly. The approach is more
expensive and computationally intensive than marker gene
sequencing because it requires sequencing to be carried out at
a much higher depth. However, it has the advantages of avoid-
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information on both the function and composition of microbio-
tas, thereby providing information at much greater resolution
(Walker et al. 2014; Almeida et al. 2019). For example, a recent
metagenomic analysis of the human gut microbiota from over
eleven thousand individuals identified 1952 candidate bacterial
species that have not yet been cultured and increased the known
phylogenetic diversity of the gut microbiota almost three-fold
(Almeida et al. 2019). Furthermore, these new genomes were esti-
mated to encode hundreds of new biosynthetic gene clusters,
revealing valuable clues about the potential functionalities of
these novel candidate species.
In principle, full shotgun metagenomics can also be applied
to mycobiota studies, but further advances are essential before
fungal metagenomes can be analyzed more accurately. In par-
ticular, the lack of non-redundant and comprehensive fungal
databases presents one of the most significant limitations. The
accuracy of sequence classification depends fundamentally on
the quality of the reference database, and, due to the large num-
ber of microbial species that have not yet been identified or
genome sequenced, the existing databases are incomplete. This
problem is gradually being lessened however, by the contin-
ual addition of genomes from newly isolated species (see Cul-
turomics) and metagenome-assembled genomes (MAGs), which
can provide reasonably accurate draft genomes for uncultured
organisms.
Metagenomics can also be complemented by other -omic
approaches to increase the power of meta-analyses. For exam-
ple, metagenomics is being combined with meta-transcriptomic
[i.e. the combined transcriptomes of the microbial community
as a whole (Martinez et al. 2016; Franzosa et al. 2018)], proteomic
(Van Belkum et al. 2018; Zhou et al. 2019), and metabolomic
data sets (Smirnov et al. 2016; Yachida et al. 2019). Major soft-
ware challenges must be addressed to improve the efficiency
with which these different data sets can be integrated. For
example, linking a metabolic gene to its transcript is relatively
straightforward, but linking these to the corresponding enzyme
and metabolic reaction is less so. Nevertheless, studies such as
these are enhancing the associations between the composition
of the gut microbiota and disease state for numerous condi-
tions, including cancer, diabetes and inflammatory bowel dis-
eases (Erickson et al. 2012; Smirnov et al. 2016; Zhang et al. 2018;
Yachida et al. 2019; Zhou et al. 2019). These technologies have
the potential to revolutionise our understanding of fungus-host-
microbiota interactions and, as a result, our ability to develop
personalised therapeutic strategies for individuals at risk of life-
threatening fungal infections.
Culturomics
In the early 2010s, the use of high throughput culturing cou-
pled to MALDI-ToF mass spectrometry (MS) revolutionised clin-
ical microbiology (Seng et al. 2009; Bizzini et al. 2010; van Veen,
Claas and Kuijper 2010). This has since been termed ‘culturomics’
(Lagier et al. 2012). In brief, culturomics can identify atypical
bacteria by combining multiple culture conditions (Beijerinck
1901; Weinstein 1996) with MALDI-ToF MS and 16S rRNA gene
sequencing. The pioneering study used 212 culture conditions
(Lagier et al. 2012), which was subsequently reduced to 18 con-
ditions (Lagier et al. 2015) and recently the overall workload has
been further reduced (Chang et al. 2019). Culturomics permits
the identification of microbial minorities present at concentra-
tions lower than 1e + 05 CFU/mL, which can encompass up to
65% of bacterial species in a given sample (Lagier et al. 2012).
This not only enables a better description of the bacterial diver-
sity (Dubourg et al. 2014), but also provides viable microbes for
downstream analysis. Downstream characterisations of the new
species can include pathogenic potential, metabolic functional-
ity and interactions with other residents of the microbiota stud-
ied.
Newly identified species whose genomes have been
sequenced can be used to identify previously found, yet uniden-
tified, operational taxonomic units (OTUs), thus filling gaps
in sequence-based analyses (Rinke et al. 2013; Lagier et al.
2016). Between 2015, when 2172 different species cultured
from different human body sites were reported (Hugon et al.
2015), and 2018, 288 new species were isolated by culturomics
(Bilen et al. 2018). Therefore, culturomics and metagenomics are
complementary techniques, with an overlap as small as 15%
of detected species in a given sample (Lagier et al. 2012, 2015;
Pfleiderer et al. 2013; Dubourg et al. 2014; Mailhe et al. 2018).
Models for the experimental dissection of
Fungus-Host-Microbiota interactions
Model experimental systems are essential for the detailed
mechanistic dissection of disease establishment and progres-
sion in humans. Models of fungal infection can simulate the pro-
cess with some degree of accuracy, but they never recapitulate
human infections perfectly. Therefore, selecting an appropri-
ate model is a crucial step that requires consideration of many
parameters, such as similarity to the human situation, cost,
workload, throughput and ethical concerns (Maccallum 2012;
Brunke et al. 2015; Poupet et al. 2020). It is important to recon-
sider the relevance of a model to the human condition, and to
clearly define the limitations of the model as well as the aspects
of the human infection that are recapitulated by the model.
Mucosa simulating models
Rodents, particularly mouse models, have been used extensively
to study vaginal and oral candidiasis (Rahman et al. 2007; Solis
and Filler 2012; Cassone and Sobel 2016), as well as systemic can-
didiasis (MacCallum and Odds 2005; Szabo and MacCallum 2011;
Brunke et al. 2015), allowing investigators to better understand
the pathogenicity of C. albicans. However, there are significant
differences between the immune systems of mice and humans
(Mestas and Hughes 2004). Also, most laboratory mice are not
naturally colonised by C. albicans and therefore do not develop a
primed immunity to this opportunistic pathogen (Cassone and
Sobel 2016). Moreover, the GI microbiota established in labora-
tory rodents generally mediates colonisation resistance against
C. albicans. Thus, antibiotic treatment is required for prolonged
high-level colonisation of the murine gut by C. albicans (Conti,
Huppler et al. 2014). Oral models generally focus on infection,
rather than colonisation, and immunosuppressive treatment is
usually required to induce OPC (Solis and Filler 2012). Also, to
study VVC in mice, oestrogen treatment is necessary to facili-
tate vaginal colonisation by C. albicans (Cassone and Sobel 2016).
Alternative in vivo mammalian models have been used to
study Fungus-Host-Microbiota interactions, such as piglets and
non-human primates, which are naturally colonised by C. albi-
cans. However, these are cost- and labour-intensive and present
ethical challenges (Steele, Ratterree and Fidel 1999; Cassone and
Sobel 2016; M Jaeger et al. 2019). Under these circumstances,
model hosts of lower phylogenetic or ontogenetic stage can pro-
vide alternative platforms to study C. albicans infections. Non-
mammalian models that have been exploited to study C. albi-
cans pathogenesis include a chorio-allantoic membrane chicken
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2002; Gow et al. 2003; Jacobsen et al. 2011; Tobin, May and
Wheeler 2012; Brunke et al. 2015).
In vitro cell culture systems also provide useful models of
C. albicans infection. These are less expensive, provide higher
throughput and present fewer ethical concerns compared to
in vivo models. For example, static cell culture models that
mimic C. albicans interactions with intestinal epithelial cells
have been used to dissect processes involved in translocation
through intestinal barriers (Allert et al. 2018). Also, in vitro cir-
culatory C. albicans-endothelium interaction models have been
used to study endothelial adhesion events under conditions of
physiological blood pressure (Wilson and Hube 2010). Recon-
stituted Human Epithelium (RHE) uses Transwell R© technology
to form polarised epithelia and allows easy access to the api-
cal and basolateral compartments for infection studies (Schaller
et al. 2006). Such models closely recapitulate the histology of nor-
mal vaginal and oral mucosae and relevant aspects of innate
immune responses (Schaller et al. 2005; Yadev et al. 2011) and
can mimic epithelial interactions with phagocytes (Weindl et al.
2007). However, RHE models do have limitations, such as the lack
of supporting cell types, the absence of mucins, non-constant
desquamation, and the overgrowth of microbes due to static
conditions (Tabatabaei, Moharamzadeh and Tayebi 2020). These
limitations need to be addressed to gain accurate views of fungal
infection.
Recently, human cell lines were incorporated into an oral-
mucosa-on-a-chip model to study host-microbiota interactions
(Rahimi et al. 2018). Also, oral mucosa organoids, which reca-
pitulate the original tissue genetically, histologically and func-
tionally, have been established (Driehuis et al. 2019). In princi-
ple, these organoids could be developed to integrate, for exam-
ple, supporting cells and saliva, to further enhance their rele-
vance to the natural oral mucosa. Organ-on-a-chip models of
vaginal infection are under development (https://gtr.ukri.org/p
rojects?ref=studentship-1818626; https://ncats.nih.gov/tissuech
ip/chip/female). Ideally, these models would include iron restric-
tion and hypoxia as these conditions are known to influence
the behaviour of C. albicans (Moosa et al. 2004; Sosinska et al.
2008; Rastogi et al. 2016; Pradhan et al. 2018, 2019). In the future,
organ-on-a-chip models of oral and vaginal infection will exploit
microfluidic platforms to combine patient-derived primary cells
and microbes to represent donor variability and permit the
development of predictive and potentially personalized infec-
tion models.
Gut simulating models
Models are also critical for the experimental dissection of host-
microbiota interactions in the GI tract. These include organoid
models as well as specialised fermentation systems (Fehlbaum
et al. 2015; Park et al. 2017; Bein et al. 2018; Pearce et al. 2018; Pham
et al. 2019), but the co-culturing of human and microbial cells
remains a technical challenge. L. rhamnosus has been shown
recently to modulate C. albicans pathogenicity in a commensal-
like co-culture model (Graf et al. 2019). A similar model, involving
co-culture of intestinal epithelial cells and M-cells, revealed that
C. albicans translocate preferentially through the M-cell (Albac
et al. 2016). These models are high-throughput, cost-efficient and
able to recapitulate epithelial cell diversity by co-culturing dif-
ferent epithelial cell types. Nevertheless, such models do not
provide the complex tissue architecture of the intestinal epithe-
lium in vivo and, due to the static conditions, they only offer a
short assay window before rapid microbial overgrowth occurs
(Albac et al. 2016; Park et al. 2017; Pearce et al. 2018; Graf et al.
2019).
On-chip technologies permit the culture of human cells
under perfusion, enabling their differentiation into a polarised
columnar epithelium (Hyun Jung Kim et al. 2016; Trietsch
et al. 2017). This has been extended to develop an immuno-
competent intestine-on-a-chip model using caco-2 epithelial
cells, endothelial cells and peripheral blood mononuclear cells
(PBMCs) to study the interaction between C. albicans and pro-
biotic L. rhamnosus (Maurer et al. 2019). Although this model
already provides three-dimensional structures that resemble
organotypic microanatomical structures and mimic microphys-
iological niches of the human intestine, further improvements
to increase mucosa cellular diversity and mucus production are
possible (Pan et al. 2015; Pearce et al. 2018). In the future, long-
term cultures of patient-derived intestinal organoids may be
feasible, which opens new avenues for the development of gut
models that are even more physiologically relevant (Sato et al.
2009; Mottawea et al. 2019). Patient-derived ileal organoids and
faecal samples have been used to culture a complex micro-
biota in an anaerobic gut-on-a-chip model for up to 5 days
(Jalili-Firoozinezhad et al. 2019). This type of model is important
because it permits the analysis of donor variability and poten-
tially allows the development of personalised therapies.
Fermentation-based models provide powerful in vitro tools
that permit the dissection of microbial processes in the human
GI tract. Static batch fermentations with faecal inocula are
the simplest and most frequently used models (Walker et al.
2005). These have provided a powerful first approach to study
bacterial-fungal interactions and to screen novel therapeutics,
but they do not recapitulate the richness of GI compartments
(Hillman et al. 2017). Therefore, multicompartmental models
have been developed (Guerra et al. 2012; Venema and van den
Abbeele 2013). These often contain three-stage culture reac-
tors (Gibson, Cummings and Macfarlane 1988) that can repro-
duce differences between proximal (acidic, carbohydrate-rich)
and distal colonic regions (neutral, carbohydrate-depleted). The
multicompartmental M-SHIME system is a powerful tool that
permits the analysis of complex, rich and relatively stable micro-
bial communities within GI compartments from the stomach
to descending colon (Van de Wiele et al. 2015; Molly, Vande
Woestyne and Verstraete 1993). This model has been used to
study bacterial-bacterial interactions and the impact of diet and
drugs on these interactions (Sivieri et al. 2014; Van den Abbeele
et al. 2016; Marzorati et al. 2017; Rivière et al. 2018; Lambrecht
et al. 2019).
Despite their power, these fermentation systems have rarely
been used to examine fungal- bacterial interactions. In two stud-
ies, C. albicans colonisation and outgrowth was shown to be
strongly correlated with antibiotic treatment, but mitigated by
L. plantarum (Payne et al. 2003; Wynne et al. 2004). However, more
recent work has shown that it is important to include the mucus
layer to properly simulate the human gut environment in vitro
(Van den Abbeele, Van de Wiele et al. 2011; Van den Abbeele,
Gérard et al. 2011; Van den Abbeele et al. 2013). Indeed, the pres-
ence of mucus influenced interactions between the yeast Sac-
charomyces boulardii and L. rhamnosus GG and their ability to limit
the outgrowth of toxigenic E. coli (Moens et al. 2019). Therefore,
a M-SHIME-based system that includes a mucus-rich environ-
ment (Van den Abbeele et al. 2012) would seem most appropriate
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SUMMARY AND OUTLOOK
To summarise, it is clear that the interactions between C. albi-
cans, the human host, and the local microbiota have a major
impact upon the likelihood of mucosal and systemic infections
and the severity of these infections. It is also apparent that
these fungus-host-microbiota interactions are dynamic, itera-
tive and enormously complex (Fig. 8). This immense complex-
ity is increased further by the genetic and phenotypic varia-
tion within the species of C. albicans, and by numerous factors
that contribute to the variability of individuals and their micro-
biotas. Yet this complexity must be addressed and defined if
the research community is to develop: (i) sensitive and accu-
rate diagnostics capable of distinguishing C. albicans infection
from commensalism, and at an early stage when the infec-
tion is more amenable to therapy; (ii) novel and efficacious
anti-fungal therapies that complement the limited antifun-
gal drugs that are currently available, and that address the
problematic emergence of drug resistance and drug resistant
species; (iii) tests that quickly establish whether a particular
patient is at risk of developing severe candidaemia or recur-
rent candidiasis and (iv) personalised therapeutic strategies
that address the specific make-up and needs of the individual
patient.
Despite these challenges, our increased understanding
of antifungal immunity and responses is offering potential
immunotherapeutic opportunities (De Luca et al. 2013; David-
son, Netea and Kullberg 2018). Effective anti-Candida vaccines,
which have proven elusive for so long, are now in sight (Cassone
2015; De Bernardis et al. 2018; Edwards et al. 2018). Our deeper
comprehension of fungal immune evasion strategies affords the
potential to block these phenotypes and thereby enhance the
efficacy of natural antifungal immunity mechanisms (Childers
et al. 2020). Significantly, the dramatic expansion in genomic
and phenotypic datasets for clinical isolates of C. albicans is pro-
viding a much clearer picture of the nature of fungal variabil-
ity and in-patient evolution (Selmecki, Forche and Berman 2006;
Ford et al. 2014; Hirakawa et al. 2015; Ropars et al. 2018; Sitterlé
et al. 2019). This information is vital because it will reveal ways
in which this microevolution might be inhibited or exploited
therapeutically. This information will also highlight essential
fungal processes that are less prone to variability and hence
present better therapeutic targets. Rapid advances in metage-
nomics and culturomics are highlighting fungal-bacterial asso-
ciations between the gut microbiota that are likely to yield use-
ful prognostic tools for patients at risk of systemic candidiasis
(Yachida et al. 2019). Our increased knowledge of local fungus-
microbiota interactions is facilitating the development of probi-
otic therapies to address VVC, OPC and C. albicans colonisation
of the GI tract (Romeo et al. 2011; Hu et al. 2013; Morais et al. 2017;
Vladareanu et al. 2018). In the future, the availability of effective
probiotics should help to reduce our dependence on antifungal
drugs while, at the same time, enhancing antifungal immunity
(Ubeda and Pamer 2012).
How relevant are these points to other fungal pathogens
of humans, such as Aspergillus, Cryptococcus, Pneumocystis and
other pathogenic Candida species? Pathogenic Aspergillus and
Cryptococcus species are environmental fungi that infect humans
via the lung. Therefore, while fundamental principles relating
to local antifungal immunity, immunotherapy and microbiota-
mediated colonisation resistance are clearly of relevance
(Armstrong-James et al. 2017; Dumas et al. 2018; Hernández-
Santos et al. 2018; Drummond and Lionakis 2019; Maschirow,
Suttorp and Opitz 2019; Warris, Bercusson and Armstrong-James
2019), the specific details will differ significantly. Pneumocys-
tis jirovecii also infects the lung, but this fungus is an intra-
cellular parasite that is obligately associated with its human
host. In this case, the lung microbiota has not been particularly
informative in distinguishing infected from uninfected patients
(Kehrmann et al. 2017). Although other Candida pathogens may
infect from environmental reservoirs, these species cause sim-
ilar types of infection to C. albicans, and therefore the points
raised in this review will be of general relevance to these species.
However, some differences in tissue tropism and patient type
exist between species (Sullivan et al. 1995; Silva et al. 2012; Pammi
et al. 2013), and some species differ in their immune avoid-
ance strategies (Brunke and Hube 2013; Kasper, Seider and Hube
2015). Nevertheless, the importance of the general principles
discussed in this C. albicans-oriented review cannot be under-
stated, most notably the major impact of variability in the fun-
gus, the individual host, and the local microbiota upon disease
severity and outcome (Carvalho et al. 2010; Farrer et al. 2015;
Hube 2015; Ballard et al. 2018; Stone et al. 2019; Vandeplassche
et al. 2019).
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Kong EF, Tsui C, Kucharı́ková S et al. Commensal Protection of
Staphylococcus aureus against Antimicrobials by Candida
albicans Biofilm Matrix. MBio 2016;7.
Koo H, Andes DR, Krysan DJ. Candida-streptococcal inter-
actions in biofilm-associated oral diseases. PLoS Pathog
2018;14:e1007342.
Kornitzer D. Regulation of Candida albicans Hyphal Morphogen-
esis by Endogenous Signals. J Fungi (Basel) 2019;5.
Korn T, Bettelli E, Oukka M et al. IL-17 and Th17 Cells. Annu Rev
Immunol 2009;27:485–517.
Korpela K et al. Intestinal microbiota development and gesta-
tional age in preterm neonates. Sci Rep 2018;8:2453.
Kos I, Patterson MJ, Znaidi S et al. Mechanisms Underly-
ing the Delayed Activation of the Cap1 Transcription Fac-
tor in Candida albicans following Combinatorial Oxidative
and Cationic Stress Important for Phagocytic Potency. MBio
2016;7:e00331.
Kovachev SM, Vatcheva-Dobrevska RS. Local Probiotic Therapy
for Vaginal Candida albicans Infections. Probiotics Antimicrob
Proteins 2015;7:38–44.
Kraneveld EA, Buijs MJ, Bonder MJ et al. The relation between
oral Candida load and bacterial microbiome profiles in Dutch
older adults. PLoS One 2012;7:e42770.
Krishnakumari V, Rangaraj N, Nagaraj R. Antifungal activi-
ties of human beta-defensins HBD-1 to HBD-3 and their C-
terminal analogs Phd1 to Phd3. Antimicrob Agents Chemother
2009;53:256–60.
Kumamoto CA. Inflammation and gastrointestinal Candida col-
onization. Curr Opin Microbiol 2011;14:386–91.
Kumamoto CA. Molecular mechanisms of mechanosensing and
their roles in fungal contact sensing. Nat Rev Microbiol
2008;6:667–73.
Kumar PS, Mason MR, Brooker MR et al. Pyrosequencing reveals
unique microbial signatures associated with healthy and







sre/article/45/3/fuaa060/6000215 by guest on 25 Septem
ber 2021
d’Enfert et al. 43
Kumar V et al. Immunochip SNP array identifies novel genetic
variants conferring susceptibility to candidaemia. Nat Com-
mun 2014;5:4675.
Kurt-Jones EA, Mandell L, Whitney C et al. Role of toll-like recep-
tor 2 (TLR2) in neutrophil activation: GM-CSF enhances TLR2
expression and TLR2-mediated interleukin 8 responses in
neutrophils. Blood 2002;100:1860–68.
Kurtz J, Franz K. Innate defence: evidence for memory in inver-
tebrate immunity. Nature 2003;425:37–38.
Kuznets G et al. A relay network of extracellular heme-binding
proteins drives C. albicans iron acquisition from hemoglobin.
PLoS Pathog 2014;10:e1004407.
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Wüthrich M, Deepe GS, Klein B. Adaptive immunity to fungi.
Annu Rev Immunol 2012;30:115–48.
Xie J et al. White-opaque switching in natural MTLa/α iso-
lates of Candida albicans: evolutionary implications for
roles in host adaptation, pathogenesis, and sex. PLoS Biol
2013;11:e1001525.
Xu C, Zhu H, Qiu P. Aging progression of human gut microbiota.
BMC Microbiol 2019;19: 236.
Xu H, Sobue T, Bertolini M et al. S. oralis activates the Efg1 fila-
mentation pathway in C. albicans to promote cross-kingdom
interactions and mucosal biofilms. Virulence 2017;8:1602–17.
Xu H, Sobue T, Bertolini M et al. Streptococcus oralis and Can-
dida albicans Synergistically Activate μ-Calpain to Degrade
E-cadherin From Oral Epithelial Junctions. J Infect Dis
2016;214:925–34.
Xu H, Sobue T, Thompson A et al. Streptococcal co-infection
augments Candida pathogenicity by amplifying the mucosal
inflammatory response. Cell Microbiol 2014;16:214–31.
Xu J, Mitchell TG. Geographical differences in human oral yeast
flora. Clin Infect Dis 2003;36:221–4.
Xu S, Shinohara ML. Tissue-Resident Macrophages in Fungal
Infections. Front Immunol 2017;8:1798.
Xu X-L, Lee RTH, Fang H-M et al. Bacterial peptidoglycan trig-
gers Candida albicans hyphal growth by directly activating
the adenylyl cyclase Cyr1p. Cell Host Microbe 2008;4:28–39.
Yachida S et al. Metagenomic and metabolomic analyses reveal
distinct stage-specific phenotypes of the gut microbiota in
colorectal cancer. Nat Med 2019;25:968–76.
Yadev NP, Murdoch C, Saville SP et al. Evaluation of tissue engi-
neered models of the oral mucosa to investigate oral candidi-
asis. Microb Pathog 2011;50:278–85.
Yang D, Oppenheim JJ. Alarmins and antimicrobial immunity.
Med Mycol 2009;47 Suppl 1:S146–53.
Yang F, Teoh F, Tan ASM et al. Aneuploidy Enables Cross-
Adaptation to Unrelated Drugs. Mol Biol Evol 2019;36:1768–82.
Yan L, Yang C, Tang J. Disruption of the intestinal mucosal barrier
in Candida albicans infections. Microbiol Res 2013;168:389–95.
Yano J, Lilly E, Barousse M et al. Epithelial cell-derived S100
calcium-binding proteins as key mediators in the hallmark
acute neutrophil response during Candida vaginitis. Infect
Immun 2010;78:5126–37.
Yano J, Noverr MC, Fidel PL. Vaginal Heparan Sulfate Linked to
Neutrophil Dysfunction in the Acute Inflammatory Response
Associated with Experimental Vulvovaginal Candidiasis.
MBio 2017;8.
Yano J, Palmer GE, Eberle KE et al. Vaginal epithelial cell-derived
S100 alarmins induced by Candida albicans via pattern
recognition receptor interactions are sufficient but not nec-
essary for the acute neutrophil response during experimen-
tal vaginal candidiasis. Infect Immun 2014;82:783–92.
Yano J, Sobel JD, Nyirjesy P et al. Current patient perspectives
of vulvovaginal candidiasis: incidence, symptoms, manage-
ment and post-treatment outcomes. BMC Womens Health
2019;19:48.
Yapar N. Epidemiology and risk factors for invasive candidiasis.
Ther Clin Risk Manag 2014;10:95–105.
Yatsunenko T et al. Human gut microbiome viewed across age
and geography. Nature 2012;486:222–7.
Yin Z et al. Proteomic response to amino acid starvation in
Candida albicans and Saccharomyces cerevisiae. Proteomics
2004;4:2425–36.
Zaneveld JR, McMinds R, Vega Thurber R. Stress and stabil-
ity: applying the Anna Karenina principle to animal micro-
biomes. Nat Microbiol 2017;2:17121.
Zarrinpar A, Chaix A, Xu ZZ et al. Antibiotic-induced microbiome
depletion alters metabolic homeostasis by affecting gut sig-
naling and colonic metabolism. Nat Commun 2018;9:2872.
Zelante T et al. Sensing of mammalian IL-17A regulates fungal







sre/article/45/3/fuaa060/6000215 by guest on 25 Septem
ber 2021
d’Enfert et al. 55
Zelante T et al. Tryptophan catabolites from microbiota engage
aryl hydrocarbon receptor and balance mucosal reactivity via
interleukin-22. Immunity 2013;39:372–85.
Zhai B et al. High-resolution mycobiota analysis reveals dynamic
intestinal translocation preceding invasive candidiasis. Nat
Med 2020;26:59–64.
Zhang N, Magee BB, Magee PT et al. Selective Advantages of
a Parasexual Cycle for the Yeast Candida albicans. Genetics
2015;200:1117–32.
Zhang X et al. Metaproteomics reveals associations between
microbiome and intestinal extracellular vesicle proteins
in pediatric inflammatory bowel disease. Nat Commun
2018;9:2873.
Zheng W et al. Metagenomic sequencing reveals altered
metabolic pathways in the oral microbiota of sailors during
a long sea voyage. Sci Rep 2015;5:9131.
Zhou W et al. Longitudinal multi-omics of host-microbe dynam-
ics in prediabetes. Nature 2019;569:663–71.
Zhou X, Hansmann MA, Davis CC et al. The vaginal bacte-
rial communities of Japanese women resemble those of
women in other racial groups. FEMS Immunol Med Microbiol
2010;58:169–81.
Zhou Y et al. Biogeography of the ecosystems of the healthy
human body. Genome Biol 2013;14:R1.
Zhu L-L, Zhao X-Q, Jiang C et al. C-type lectin receptors Dectin-
3 and Dectin-2 form a heterodimeric pattern-recognition
receptor for host defense against fungal infection. Immunity
2013;39:324–34.
Zielinski CE, Mele F, Aschenbrenner D et al. Pathogen-induced
human TH17 cells produce IFN-γ or IL-10 and are regulated
by IL-1β. Nature 2012;484:514–8.
Zipfel PF, Hallström T, Riesbeck K. Human complement control
and complement evasion by pathogenic microbes–tipping
the balance. Mol Immunol 2013;56:152–60.
Zipfel PF, Skerka C. Complement regulators and inhibitory pro-
teins. Nat Rev Immunol 2009;9:729–40.
Znaidi S, Barker KS, Weber S et al. Identification of the Candida
albicans Cap1p regulon. Eukaryotic Cell 2009;8:806–20.
Zoetendal EG et al. The human small intestinal microbiota is
driven by rapid uptake and conversion of simple carbohy-
drates. ISME J 2012;6:1415–26.
Zuo T et al. Gut fungal dysbiosis correlates with reduced efficacy
of fecal microbiota transplantation in Clostridium difficile
infection. Nat Commun 2018;9:3663.
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